

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

New England Journal of Medicine

358, 1431-1443

DOI: [10.1056/nejmoa0800742](https://doi.org/10.1056/nejmoa0800742)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Simvastatin and Ezetimibe in Addition to Nonpharmacological Risk Factor Modification for Achieving New Low-Density Lipoprotein Cholesterol Targets. <i>Herz</i> , 2008, 33, 362-367.	1.1	3
4	Disodium ascorbyl phytostanol phosphate. A new cholesterol-lowering drug?. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 649-650.	1.9	1
5	Carotid intima-media thickness measurements: Techniques and clinical relevance. <i>Current Atherosclerosis Reports</i> , 2008, 10, 444-450.	4.8	68
6	Late-breaking trials at the ACC scientific sessions: Insights and controversy. <i>Current Cardiology Reports</i> , 2008, 10, 247-249.	2.9	0
7	LDL reduction: How low should we go and is it safe?. <i>Current Cardiology Reports</i> , 2008, 10, 481-487.	2.9	3
8	LDL-C-Lowering therapy: Current and future therapeutic targets. <i>Current Cardiology Reports</i> , 2008, 10, 512-520.	2.9	13
9	Atherosclerosis surrogate imaging trials come of age: For better or for worse?. <i>Current Cardiology Reports</i> , 2008, 10, 521-525.	2.9	5
10	Diabetic dyslipidemia and cardiovascular risk. <i>Current Diabetes Reports</i> , 2008, 8, 421-423.	4.2	9
13	Assessment of new technologies: Surrogate endpoints versus outcomes, and the cost of health care. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 299-300.	2.1	3
14	The Implications of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial: A Return to First Principles. <i>Clinical Cardiology</i> , 2008, 31, 288-290.	1.8	5
15	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	1.5	8
16	Surrogate markers, atherosclerosis and cardiovascular disease prevention. <i>International Journal of Clinical Practice</i> , 2008, 62, 981-987.	1.7	29
17	Muddy waters: more stormy SEAS for ezetimibe. <i>International Journal of Clinical Practice</i> , 2008, 62, 1470-1473.	1.7	16
18	Drug markers questioned. <i>Nature</i> , 2008, 452, 510-1.	27.8	15
19	Form to function: current and future roles for atherosclerosis imaging in drug development. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 517-529.	46.4	68
20	Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. <i>Cardiovascular Therapeutics</i> , 2008, 26, 85-88.	2.5	5
21	Ezetimibe effectively lowers LDL cholesterol in cardiac allograft recipients on stable statin therapy. <i>Clinical Transplantation</i> , 2008, 22, 639-644.	1.6	4
22	Enhanced Hype. <i>American Journal of Cardiology</i> , 2008, 102, 368-369.	1.6	5

#	ARTICLE	IF	CITATIONS
23	ENHANCE and ONTARGET. Preventive Cardiology, 2008, 11, 179-182.	1.1	1
24	The "Null Effect" of Low-Density Lipoprotein Cholesterol Lowering on a Modest Baseline Intima-Media Thickness: Lessons Learned From the ENHANCE Trial. Preventive Cardiology, 2008, 11, 177-178.	1.1	0
25	Dyslipidemia in Youth with Diabetes: To Treat or Not to Treat?. Journal of Pediatrics, 2008, 153, 458-465.e4.	1.8	44
27	The Metabolic Syndrome. Endocrine Reviews, 2008, 29, 777-822.	20.1	1,513
30	Inherited metabolic disorders and cerebral infarction. Expert Review of Neurotherapeutics, 2008, 8, 1731-1741.	2.8	13
31	Summary of the Clinical Studies Reported in the 57th Scientific Session of the American College of Cardiology (Chicago, USA, March 30 - April 2 2008). Revista Espanola De Cardiologia (English Ed), 2008, 61, 726-737.	0.6	13
32	Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. Journal of the American College of Cardiology, 2008, 52, 2198-2205.	2.8	240
34	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T outcomes in patients with acute coronary syndromes. Journal of Clinical Lipidology, 2008, 2, 313-317.	1.5	19
35	Ezetimibe-related myopathy: A systematic review. Journal of Clinical Lipidology, 2008, 2, 328-334.	1.5	30
36	Use of Ezetimibe in the United States and Canada. New England Journal of Medicine, 2008, 358, 1819-1828.	27.0	85
37	Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?. New England Journal of Medicine, 2008, 358, 1504-1507.	27.0	92
38	Aortic valve calcification: basic science to clinical practice. Heart, 2008, 95, 616-623.	2.9	78
39	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgBT /Overlock 10 T outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	2.7	280
40	Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics, 2008, 9, 1475-1486.	1.3	70
41	Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries. Clinical Therapeutics, 2008, 30, 1508-1523.	2.5	17
43	P1.07 ROSUVASTATIN INCREASES EXTRACELLULAR ADENOSINE IN HUMANS IN VIVO: A NEW PERSPECTIVE ON CARDIOVASCULAR PROTECTION. Artery Research, 2008, 2, 94.	0.6	0
44	Use of Drugs in the Primary Prevention of Arterial Hypertension and Dyslipidemia. Revista Espanola De Cardiologia (English Ed), 2008, 61, 861-879.	0.6	0
45	Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clinic Proceedings, 2008, 83, 867-869.	3.0	12

#	ARTICLE	IF	CITATIONS
46	Clinical Update on Nursing Home Medicine: 2008. Journal of the American Medical Directors Association, 2008, 9, 460-475.	2.5	16
47	Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial. Mayo Clinic Proceedings, 2008, 83, 758-764.	3.0	83
48	Cardiopathie ischémique: le point sur le traitement pharmacologique en 2008. Medecine Des Maladies Metaboliques, 2008, 2, 241-247.	0.1	1
49	Risk Factor Management to Prevent First Stroke. Neurologic Clinics, 2008, 26, 1007-1045.	1.8	48
50	Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?. Mayo Clinic Proceedings, 2008, 83, 1299-1300.	3.0	8
51	Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Current Medical Research and Opinion, 2008, 24, 2777-2784.	1.9	3
52	Is it over for ezetimibe?. Expert Review of Cardiovascular Therapy, 2008, 6, 781-783.	1.5	8
53	Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. American Journal of Cardiovascular Drugs, 2008, 8, 233-242.	2.2	23
54	Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 357-371.	1.4	59
55	Biomarkers, Atherosclerosis and Cardiovascular Events. Expert Review of Cardiovascular Therapy, 2008, 6, 619-622.	1.5	6
57	NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 1. Heart, 2008, 95, 587-589.	2.9	0
58	Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism. Angiology, 2008, 59, 44S-48S.	1.8	1
59	Ezetimibe Alone Reduces Low-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 47, 1105-1108.	5.8	53
60	Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart, 2008, 95, 584-587.	2.9	39
61	The ENHANCE Study and Marketing Ezetimibe—Reply. JAMA - Journal of the American Medical Association, 2008, 299, 2747.	7.4	2
62	HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, S79-S85.	2.1	112
63	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. Cmaj, 2008, 179, 920-926.	2.0	37
64	Vascular form and function: two mechanisms for cardiovascular prevention. European Heart Journal, 2008, 29, 1711-1713.	2.2	1

#	ARTICLE	IF	CITATIONS
65	Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. <i>European Heart Journal</i> , 2008, 29, 2625-2633.	2.2	391
66	Validity and reliability of measurement instruments used in research. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 2276-2284.	1.0	827
67	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. <i>Future Lipidology</i> , 2008, 3, 237-255.	0.5	15
68	Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. <i>Diabetes Spectrum</i> , 2008, 21, 177-189.	1.0	11
69	Is There a Problem With Ezetimibe or Just ENHANCED Hype?. <i>Angiology</i> , 2008, 59, 661-663.	1.8	7
70	Carotid Intima-Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial. <i>Angiology</i> , 2008, 59, 77S-79S.	1.8	10
71	Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. <i>Current Medical Research and Opinion</i> , 2008, 24, 3149-3157.	1.9	7
72	Cholesterol Lowering and Ezetimibe. <i>New England Journal of Medicine</i> , 2008, 358, 1507-1508.	27.0	57
73	Use of ezetimibe during HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 218-220.	3.0	5
74	NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 2. <i>Heart</i> , 2008, 95, 589-591.	2.9	2
75	Prevention of Future Cardiovascular Disease in High-Risk Pediatric Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 131-133.	2.2	1
76	After ENHANCE: Is More LDL Cholesterol Lowering Even Better?. <i>Clinical Chemistry</i> , 2008, 54, 940-942.	3.2	20
77	Preliminary Observations From Preliminary Trial Results. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 54-57.	2.2	13
78	An Assessment of the New Lipid Screening Guidelines. <i>Pediatrics</i> , 2008, 122, 904-905.	2.1	2
79	Microsomal triglyceride transfer protein inhibition—friend or foe?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 506-508.	3.3	15
80	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 359, 529-533.	27.0	5
81	Pacific Biomarkers, Inc.. <i>Biomarkers in Medicine</i> , 2008, 2, 221-227.	1.4	2
83	The Time for Cardiovascular Inflammation Reduction Trials Has Arrived. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1222-1224.	2.4	23

#	ARTICLE	IF	CITATIONS
84	Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Physician and Sportsmedicine, 2008, 36, 129-131.	2.1	1
85	Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clinic Proceedings, 2008, 83, 867-869.	3.0	20
86	Patient-Important Outcomes in Registered Diabetes Trials. JAMA - Journal of the American Medical Association, 2008, 299, 2543.	7.4	194
87	Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ: British Medical Journal, 2008, 337, a2423-a2423.	2.3	610
88	Clinical trials and surrogate end points: lessons from the ENHANCE trial. Future Lipidology, 2008, 3, 353-357.	0.5	1
89	New insights in preventive cardiology and cardiac rehabilitation. Current Opinion in Cardiology, 2008, 23, 477-486.	1.8	7
90	Therapy and clinical trials. Current Opinion in Lipidology, 2008, 19, 550-551.	2.7	0
91	Beyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?. Therapy: Open Access in Clinical Medicine, 2008, 5, 487-489.	0.2	0
92	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 2008, 19, 433-434.	2.7	1
93	Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. Current Opinion in Lipidology, 2008, 19, 585-591.	2.7	2
96	Pharmacotherapy: Improving the Lipid Profile. , 0, , 57-63.		0
99	Molecular processes that handle " and mishandle " dietary lipids. Journal of Clinical Investigation, 2008, 118, 3247-3259.	8.2	142
101	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	1.0	1
102	After ENHANCE: the cholesterol hypothesis is alive and well. Medical Journal of Australia, 2008, 189, 303-304.	1.7	3
103	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vascular Health and Risk Management, 2008, 5, 31.	2.3	10
104	The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vascular Health and Risk Management, 2009, 5, 233.	2.3	21
105	New paradigm of treatment with statins in cardiovascular prevention. Monaldi Archives for Chest Disease, 2009, 72, .	0.6	0
106	Lipid-Modifying and Antiatherosclerotic Drugs. , 2009, , 341-372.		2

#	ARTICLE	IF	CITATIONS
107	Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease. <i>Journal of Receptor, Ligand and Channel Research</i> , 0, , 1.	0.7	8
108	Prospective cardiac gating of carotid three-dimensional ultrasound. <i>Medical Physics</i> , 2009, 36, 3168-3175.	3.0	4
109	Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2036.	0.1	1
110	Diab�te de�type 2: prise en�charge efficace du�risque vasculaire. <i>Sang Thrombose Vaisseaux</i> , 2009, 21, 409-415.	0.1	0
111	Facts and Ideas from Anywhere. <i>Baylor University Medical Center Proceedings</i> , 2009, 22, 178-187.	0.5	2
112	Disappointing Recent Cholesterol-Lowering Drug Trials: Is It Not Time for a Full Reappraisal of the Cholesterol Theory?. <i>World Review of Nutrition and Dietetics</i> , 2009, 100, 80-89.	0.3	3
113	Are Statin Effects Mediated Through, or in Spite of, Their Cholesterol-lowering Action?. <i>Angiology</i> , 2009, 60, 262-263.	1.8	0
115	Drugs for Children with Hypercholesterolemia: Be Cautious. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2009, 22, 483-5.	0.9	3
116	Perspectives on low-density lipoprotein cholesterol goal achievement. <i>Current Medical Research and Opinion</i> , 2009, 25, 431-447.	1.9	39
117	Hypertension and Diabetes: Should We Treat Early Surrogates?. <i>Diabetes Care</i> , 2009, 32, S290-S293.	8.6	2
118	Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness. <i>Clinical Trials</i> , 2009, 6, 305-319.	1.6	7
119	Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 569-581.	1.4	40
120	Moderately Decreased Cholesterol Absorption Rates Are Associated With a Large Atheroprotective Effect. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1745-1750.	2.4	21
121	A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 589-598.	3.0	15
122	Changing the Diabetes Treatment Paradigm. <i>Archives of Internal Medicine</i> , 2009, 169, 1241.	3.8	0
123	Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8). <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2009, 9, 18-29.	0.5	50
124	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	3.0	11
125	Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. <i>Mayo Clinic Proceedings</i> , 2009, 84, 353-361.	3.0	21

#	ARTICLE	IF	CITATIONS
126	Clinical pharmacology, biomarkers and personalized medicine: education please. Biomarkers in Medicine, 2009, 3, 685-700.	1.4	9
127	Imaging outcomes in cardiovascular clinical trials. Nature Reviews Cardiology, 2009, 6, 524-531.	13.7	8
128	Communicating Medical News – Pitfalls of Health Care Journalism. New England Journal of Medicine, 2009, 360, 1-3.	27.0	119
129	The HALTS Trial – Halting Atherosclerosis or Halted Too Early?. New England Journal of Medicine, 2009, 361, 2178-2180.	27.0	34
130	Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review. Current Medicinal Chemistry, 2009, 16, 1799-1805.	2.4	23
131	An Emerging Paradigm in Atherosclerosis: Focus on Subclinical Disease. Postgraduate Medicine, 2009, 121, 49-59.	2.0	9
132	Review of ARBITER 2: Extended-Release Niacin Added to Statin Therapy Slows the Progression of Atherosclerosis. Postgraduate Medicine, 2009, 121, 195-198.	2.0	5
133	History of the cholesterol hypothesis in Britain. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 436-438.	0.5	4
134	The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. Journal of Lipid Research, 2009, 50, 334-341.	4.2	81
135	Anti-Inflammatory Effects of Fibrates: An Overview. Current Medicinal Chemistry, 2009, 16, 676-684.	2.4	26
136	Implications of recent clinical trials on pay-for-performance. American Journal of Health-System Pharmacy, 2009, 66, 864-867.	1.0	7
137	Statin Therapy with Ezetimibe or Niacin in High-Risk Patients. New England Journal of Medicine, 2009, 361, 2180-2183.	27.0	43
138	Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scandinavian Cardiovascular Journal, 2009, 43, 285-291.	1.2	42
139	ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2009, 301, 1131.	7.4	128
140	History of the cholesterol hypothesis in Britain. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 750-751.	0.5	0
141	In Vivo Quantification of Carotid Artery Wall Dimensions. Circulation: Cardiovascular Imaging, 2009, 2, 235-242.	2.6	78
142	Variability in the prevalence of radiographic stigmata and in their use for profiling disease severity makes comparisons more complicated. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 751-752.	0.5	0
143	Evidence for Statin Pleiotropy in Humans. Circulation, 2009, 119, 131-138.	1.6	208

#	ARTICLE	IF	CITATIONS
144	Prognostic impact of hsâ€CRP and ILâ€6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 425-432.	1.2	58
145	Pharmacistsâ€™ role in facilitating evidence-based prescribing for unlabeled use of medications. American Journal of Health-System Pharmacy, 2009, 66, 1735-1739.	1.0	5
146	The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk. Annals of Pharmacotherapy, 2009, 43, 2021-2030.	1.9	16
147	Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. Lupus, 2009, 18, 383-386.	1.6	17
148	Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 963-968.	2.4	37
149	Major Recent Trials in Cardiovascular Diseases. Postgraduate Medicine, 2009, 121, 15-24.	2.0	3
150	LDL-Cholesterol is the King. Angiology, 2009, 60, 387-388.	1.8	0
151	Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract. Current Pharmaceutical Design, 2009, 15, 490-516.	1.9	50
152	American Diabetes Association Indications for Statins in Diabetes. Diabetes Care, 2009, 32, S384-S391.	8.6	53
153	After the Failure of Enhanced Cholesterol Lowering in Familial Hypercholesterolemia, SEAS of Problems with Ezetimibe. Angiology, 2009, 60, 127-128.	1.8	3
154	Is There Evidence-based Hypolipidemic Treatment with Clinical Benefit beyond Statins?. Angiology, 2009, 60, 93-98.	1.8	3
156	Ezetimibe Treatment of Pediatric Patients with Hypercholesterolemia. Journal of Pediatrics, 2009, 154, 869-872.	1.8	52
157	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. Trends in Cardiovascular Medicine, 2009, 19, 195-201.	4.9	19
158	Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. American Journal of Cardiology, 2009, 103, 369-374.	1.6	80
159	Utility of Ezetimibe. American Journal of Cardiology, 2009, 103, 1321-1322.	1.6	1
160	Clinical and Research Applications of Carotid Intima-Media Thickness. American Journal of Cardiology, 2009, 103, 1316-1320.	1.6	52
161	Evaluating Lipid-Lowering Trials in the Twenty-First Century. American Journal of Cardiology, 2009, 103, 1325-1328.	1.6	6
162	The Editor's Roundtable: The JUPITER Trialâ€™Initial Results and Clinical Implications. American Journal of Cardiology, 2009, 103, 1417-1425.	1.6	19

#	ARTICLE	IF	CITATIONS
163	Effects of Consumption of Pomegranate Juice on Carotid Intimaâ€“Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease. American Journal of Cardiology, 2009, 104, 936-942.	1.6	119
164	Screening for Subclinical Coronary Artery Disease Measuring Carotid Intima Media Thickness. American Journal of Cardiology, 2009, 104, 1383-1388.	1.6	54
165	What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?. Seminars in Vascular Surgery, 2009, 22, 245-251.	2.8	3
167	Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transplantation, 2009, 15, 504-508.	2.4	60
169	Reconsidering the Placebo Response from a Broad Anthropological Perspective. Culture, Medicine and Psychiatry, 2009, 33, 112-152.	1.2	104
170	Heterozygous familial hypercholesterolaemia in childhood: Cardiovascular risk prevention. Journal of Inherited Metabolic Disease, 2009, 32, 699-705.	3.6	15
171	Statins and Vitamin D. Cardiovascular Drugs and Therapy, 2009, 23, 261-262.	2.6	20
172	Achieving optimum lipid-lowering goals in patients with vascular disease. Current Cardiovascular Risk Reports, 2009, 3, 323-330.	2.0	0
173	A review of trials evaluating nonstatin lipid-lowering therapies. Current Atherosclerosis Reports, 2009, 11, 64-66.	4.8	0
174	Planning primary prevention of coronary disease. Current Atherosclerosis Reports, 2009, 11, 272-280.	4.8	15
175	Fact or Fiction: The Need for Independent Pharmaceutical Policy Research. Journal of General Internal Medicine, 2009, 24, 692-694.	2.6	1
176	Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh. Indian Journal of Clinical Biochemistry, 2009, 24, 343-355.	1.9	16
177	Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 10.	3.3	58
178	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 2009, 70, 815-828.	2.4	69
179	Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDLâ€“profiles. European Journal of Clinical Investigation, 2009, 39, 463-470.	3.4	23
180	Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and metaâ€“analysis of randomized controlled trials. Journal of Internal Medicine, 2009, 265, 568-580.	6.0	183
181	Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12â€“months of treatment: the METEOR study. Journal of Internal Medicine, 2009, 265, 698-707.	6.0	39
182	Greater absolute reductions in LDL cholesterol should yield greater proportional reductions in risk of cardiovascular disease. Journal of Internal Medicine, 2009, 266, 499-501.	6.0	0

#	ARTICLE	IF	CITATIONS
183	The impact of clinical trials legislation on clinical pharmacology: problems and solutions. British Journal of Clinical Pharmacology, 2009, 67, 487-493.	2.4	15
184	The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology and Therapeutics, 2009, 86, 32-43.	4.7	60
185	Targeting treatment using calculated cardiovascular disease risk: Effective? A shot in the dark? Or is it time to change the paradigm?. International Journal of Clinical Practice, 2009, 63, 1785-1791.	1.7	2
186	Longitudinal Ultrasound Evaluation of Carotid Atherosclerosis in One, Two and Three Dimensions. Ultrasound in Medicine and Biology, 2009, 35, 367-375.	1.5	42
187	Three-dimensional Ultrasound Quantification of Intensive Statin Treatment of Carotid Atherosclerosis. Ultrasound in Medicine and Biology, 2009, 35, 1763-1772.	1.5	87
188	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 966-977.	4.4	42
189	Rediscovering bile acid sequestrants. Diabetes, Obesity and Metabolism, 2009, 11, 1114-1121.	4.4	17
190	Do plant sterol concentrations correlate with coronary artery disease in type 1 diabetes? A report from the Pittsburgh Epidemiology of Diabetes Complications Study. Journal of Diabetes, 2009, 1, 112-117.	1.8	7
191	Ezetimibe â€“ new antiâ€œatherogenic properties?. British Journal of Pharmacology, 2009, 156, 1216-1217.	5.4	4
192	Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipidâ€œlowering effect. British Journal of Pharmacology, 2009, 156, 1218-1227.	5.4	68
193	Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Reportâ€œPart I. Value in Health, 2009, 12, 1044-1052.	0.3	305
194	Cholesterol Goals: Moving from Numbers to Treatment. Clinical Cardiology, 2009, 32, 106-108.	1.8	0
195	Â€Ezetimibe - an update. Drug and Therapeutics Bulletin, 2009, 47, 91-95.	0.3	3
196	Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients in vitro. Transplant Immunology, 2009, 21, 179-182.	1.2	24
197	Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 580-586.	2.6	49
201	Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008. American Journal of Medicine, 2009, 122, S38-S50.	1.5	36
202	Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. Journal of Lipid Research, 2009, 50, 730-739.	4.2	93
203	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2009, 53, 1326-1337.	2.8	7

#	ARTICLE	IF	CITATIONS
204	End Points for Clinical Trials in Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 2248-2258.	2.8	92
205	Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis. Journal of Clinical Lipidology, 2009, 3, 138-142.	1.5	34
206	At Sea with SEAS: The First Clinical Endpoint Trial for Ezetimibe, Treatment of Patients with Mild to Moderate Aortic Stenosis, Ends with Mixed Results and More Controversy. Heart Lung and Circulation, 2009, 18, 343-346.	0.4	12
207	The ethics of clinical trials. Anaesthesia and Intensive Care Medicine, 2009, 10, 98-101.	0.2	1
209	Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinology and Metabolism Clinics of North America, 2009, 38, 79-97.	3.2	84
210	Pleiotropic Effects of Statins and Beyond. Cardiology, 2009, 112, 1-3.	1.4	5
211	The Vytorin on Carotid Intimaâ€‘Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. Journal of Clinical Pharmacology, 2009, 49, 838-847.	2.0	68
212	Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids in Health and Disease, 2009, 8, 56.	3.0	8
213	Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids in Health and Disease, 2009, 8, 41.	3.0	28
214	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals. Mayo Clinic Proceedings, 2009, 84, 811-821.	3.0	62
215	Extended-Release Niacin or Ezetimibe and Carotid Intimaâ€‘Media Thickness. New England Journal of Medicine, 2009, 361, 2113-2122.	27.0	610
217	Lipid Management in the Geriatric Patient. Endocrinology and Metabolism Clinics of North America, 2009, 38, 185-206.	3.2	5
218	Stearate-Enriched Plant Sterol Esters Lower Serum LDL Cholesterol Concentration in Normo- and Hypercholesterolemic Adults. Journal of Nutrition, 2009, 139, 1445-1450.	2.9	39
219	Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology, 2009, 5, 150-159.	9.6	656
220	Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs. Pharmacoeconomics, 2009, 27, 435-438.	3.3	36
221	Ezetimibe/simvastatin. Expert Opinion on Drug Safety, 2009, 8, 715-725.	2.4	8
222	Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis, 2009, 203, 41-44.	0.8	37
223	The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis, 2009, 204, 330-333.	0.8	32

#	ARTICLE	IF	CITATIONS
224	Surrogate markers in clinical trials—Challenges and opportunities. <i>Atherosclerosis</i> , 2009, 206, 8-16.	0.8	49
225	Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?. <i>Atherosclerosis</i> , 2009, 205, 349-356.	0.8	37
226	Management of non-high-density lipoprotein abnormalities. <i>Atherosclerosis</i> , 2009, 207, 328-335.	0.8	22
227	How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. <i>Postgraduate Medical Journal</i> , 2009, 85, 538-545.	1.8	121
228	A winter's tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. <i>Canadian Journal of Cardiology</i> , 2009, 25, 527-532.	1.7	2
230	Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection. <i>Cerebrovascular Diseases</i> , 2009, 27, 38-47.	1.7	55
231	A Cross-sectional Study of Intima-Media Thickness, Ethnicity, Metabolic Syndrome, and Cardiovascular Risk in 2268 Study Participants. <i>Mayo Clinic Proceedings</i> , 2009, 84, 221-228.	3.0	35
232	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	3.0	5
233	Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. <i>Mayo Clinic Proceedings</i> , 2009, 84, 353-361.	3.0	17
234	Intimal Imaging With Ultrasound: What Anatomy Are We Resolving?. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 1134-1136.	2.8	0
235	Lipid Management in Children. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 171-183.	3.2	27
236	Hyperlipidemia in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 591-606.	2.6	23
237	Echocardiographic Imaging in Clinical Trials: American Society of Echocardiography Standards for Echocardiography Core Laboratories. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 755-765.	2.8	175
238	Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 207-222.	3.2	28
239	A Review of Lipid Management in Primary and Secondary Prevention. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2009, 29, 2-12.	2.1	45
240	Role of ezetimibe in the management of patients with atherosclerosis. <i>Coronary Artery Disease</i> , 2009, 20, 169-174.	0.7	7
242	The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin. <i>Transplantation</i> , 2009, 87, 771-775.	1.0	26
243	Approach to the diagnosis and management of lipoprotein disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 132-140.	2.3	19

#	ARTICLE	IF	CITATIONS
244	Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]. Current Pharmaceutical Design, 2009, 15, 463-466.	1.9	1
245	Sex-specific effect of the Î±-adducin (G460W) and ACTR1 (A1166C) polymorphism on carotid intima-media thickness. Journal of Hypertension, 2009, 27, 2165-2173.	0.5	4
246	Ezetimibe-Simvastatin Combination Therapy. American Journal of Nursing, 2009, 109, 30-31.	0.4	0
247	Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. Yearbook of Vascular Surgery, 2009, 9-11.	0.0	0
248	Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Yearbook of Cardiology, 2009, 2009, 313-315.	0.0	0
249	Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. Aids, 2009, 23, 2133-2141.	2.2	36
250	A Health Advisory Concerning Topical Anesthetics. American Journal of Nursing, 2009, 109, 30.	0.4	2
251	Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia. Annals of Internal Medicine, 2009, 151, 622.	3.9	71
252	Lessons in lipid lowering from the Stop Atherosclerosis in Native Diabetics Study (SANDS). Clinical Lipidology, 2009, 4, 523-525.	0.4	0
253	Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome. Current Pharmaceutical Design, 2009, 15, 3446-3462.	1.9	7
254	Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy. Current Pharmaceutical Design, 2009, 15, 467-478.	1.9	232
255	Statin and ezetimibe combination therapy in cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 183-188.	2.3	21
256	Therapy and clinical trials: Familial Hypercholesterolaemia and prevention of coronary artery disease. Current Opinion in Lipidology, 2009, 20, 450-451.	2.7	0
257	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. Yearbook of Cardiology, 2009, 2009, 315-317.	0.0	0
258	Role of Statins in Diabetes Complications. Current Diabetes Reviews, 2009, 5, 165-170.	1.3	9
259	Emphasizing the Burden of Proof. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 565-567.	2.2	11
260	Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology, 2010, 21, 372-377.	2.7	10
261	Evaluation and management of hyperlipidemia in children and adolescents. Current Opinion in Pediatrics, 2010, 22, 485-493.	2.0	24

#	ARTICLE	IF	CITATIONS
262	Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. <i>Current Opinion in Pediatrics</i> , 2010, 22, 398-404.	2.0	28
264	Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin/Ezetimibe Coadministration. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 1-5.	1.9	31
265	Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 241-245.	1.9	9
266	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 825-834.	2.4	2
267	Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -. <i>Circulation Journal</i> , 2010, 74, 818-826.	1.6	490
270	Statins and Cancer: A Potential Link?. <i>American Journal of Therapeutics</i> , 2010, 17, e100-e104.	0.9	2
271	Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 556-561.	2.8	2
272	Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. <i>Clinical Lipidology</i> , 2010, 5, 527-541.	0.4	2
273	Plant stanol consumption for cardiovascular health: what do we know about efficacy and safety?. <i>Clinical Lipidology</i> , 2010, 5, 827-833.	0.4	1
275	Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study. <i>Current Diabetes Reports</i> , 2010, 10, 173-175.	4.2	5
278	MR plaque imaging of the carotid artery. <i>Neuroradiology</i> , 2010, 52, 253-274.	2.2	61
279	Risk factors for cerebrovascular and cardiovascular diseases beyond age 75Âyears. <i>Journal of Neural Transmission</i> , 2010, 117, 1247-1252.	2.8	7
281	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. <i>Advances in Therapy</i> , 2010, 27, 348-364.	2.9	20
282	Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 985-989.	2.1	1
283	Migratory polyarthritis in familial hypercholesterolemia (type IIa hyperlipoproteinemia). <i>Indian Journal of Pediatrics</i> , 2010, 77, 329-331.	0.8	2
284	Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. <i>Current Atherosclerosis Reports</i> , 2010, 12, 34-42.	4.8	16
285	Management of the Patient with Statin Intolerance. <i>Current Atherosclerosis Reports</i> , 2010, 12, 48-57.	4.8	36
286	Effect of Ezetimibe on Carotid Intimal Thickness: The VYCTOR Study. <i>Current Atherosclerosis Reports</i> , 2010, 12, 288-290.	4.8	1

#	ARTICLE	IF	CITATIONS
287	Strategies to Achieve Target LDL Levels. Current Diabetes Reports, 2010, 10, 4-6.	4.2	0
288	Primary Care of the Renal Transplant Patient. Journal of General Internal Medicine, 2010, 25, 731-740.	2.6	15
290	Prevención secundaria en enfermedad cardiovascular. FMC Formacion Medica Continuada En Atencion Primaria, 2010, 17, 5-41.	0.0	0
291	Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism: Clinical and Experimental, 2010, 59, 921-926.	3.4	31
292	Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. , 2010, 126, 263-278.		37
293	Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology, 2010, 633, 62-70.	3.5	46
294	Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. American Journal of Cardiology, 2010, 105, 1289-1296.	1.6	46
295	Effect of Ezetimibe/Atorvastatin Combination on Oxidized Low Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease or Coronary Artery Disease Equivalent. American Journal of Cardiology, 2010, 106, 193-197.	1.6	18
297	Role of Ezetimibe in the Prevention of Cardiovascular Disease: Absence of Evidence. Archives of Medical Research, 2010, 41, 649-650.	3.3	6
298	Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial. Clinical Therapeutics, 2010, 32, 615-625.	2.5	81
300	NPC1L1 and cholesterol transport. FEBS Letters, 2010, 584, 2740-2747.	2.8	155
301	Subclinical Atherosclerosis: Evolving Role of Carotid Intima-Media Thickness. Preventive Cardiology, 2010, 13, 186-197.	1.1	29
302	Reporting bias in medical research - a narrative review. Trials, 2010, 11, 37.	1.6	361
303	Diminishing Efficacy of Combination Therapy, Response Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. Health Services Research, 2010, 45, 437-456.	2.0	26
304	Combined therapy in the treatment of dyslipidemia. Fundamental and Clinical Pharmacology, 2010, 24, 19-28.	1.9	81
305	Practice makes perfect: reflections on a primary care treatment-to-target study. International Journal of Clinical Practice, 2010, 64, 1006-1008.	1.7	4
306	C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine, 2010, 268, 155-161.	6.0	29
307	Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. European Journal of Clinical Investigation, 2010, 40, 187-194.	3.4	17

#	ARTICLE	IF	CITATIONS
308	Transporters as Drug Targets: Discovery and Development of NPC1L1 Inhibitors. Clinical Pharmacology and Therapeutics, 2010, 87, 117-121.	4.7	21
309	The search beyond statins. Nature Medicine, 2010, 16, 150-153.	30.7	21
310	Potential therapeutic uses for ezetimibe beyond lowering LDL to decrease cardiovascular events. Diabetes, Obesity and Metabolism, 2010, 12, 958-966.	4.4	16
311	Surrogate endpoints in clinical practice: are we providing worse care?. Internal Medicine Journal, 2010, 40, 395-398.	0.8	8
312	Completeness of Carotid Intima Media Thickness Measurements Depends on Body Composition: The RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis, 2010, 17, 526-535.	2.0	20
313	24 Cholesterinsenkung und Stabilisierung der Gefäßfunktion. , 2010, , .		0
314	Managing residual risk in patients receiving statin therapy. Medical Journal of Australia, 2010, 193, 375-376.	1.7	4
315	Optimal management of familial hypercholesterolemia: treatment and management strategies. Vascular Health and Risk Management, 2010, 6, 1079.	2.3	35
316	Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal. PLoS ONE, 2010, 5, e9220.	2.5	110
317	Identification of Novel Inhibitors of Dietary Lipid Absorption Using Zebrafish. PLoS ONE, 2010, 5, e12386.	2.5	73
318	Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vascular Health and Risk Management, 2010, 6, 1023.	2.3	35
319	Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vascular Health and Risk Management, 2010, 7, 1.	2.3	17
320	Cholesterol-lowering phytosterols: factors affecting their use and efficacy. Nutrition and Dietary Supplements, 0, , 59.	0.7	29
321	Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus. Korean Diabetes Journal, 2010, 34, 16.	0.8	1
322	Paraoxonase-1 and its Interactions with HDL. , 2010, , 99-131.		3
323	Recent cholesterol-lowering drug trials: New data, new questions. Journal of Lipid Nutrition, 2010, 19, 65-92.	0.1	2
324	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
325	Familial Hypercholesterolemia. , 2010, , 1-6.		1

#	ARTICLE	IF	CITATIONS
326	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	3.8	23
327	Pharmacotherapy Using Cardiovascular Agents: Focus on the Top 200 Drugs. <i>Journal of Pharmacy Technology</i> , 2010, 26, 213-219.	1.0	1
328	Encouraging appropriate treatment for familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 339-354.	0.4	12
329	Correlation Between Carotid Intimal/Medial Thickness and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 177-181.	2.4	309
330	The ENHANCE trial: analysis and clinical significance. <i>Clinical Lipidology</i> , 2010, 5, 161-166.	0.4	3
331	Copayment Reductions Generate Greater Medication Adherence In Targeted Patients. <i>Health Affairs</i> , 2010, 29, 2002-2008.	5.2	95
332	Designing Comparative Effectiveness Research On Prescription Drugs: Lessons From The Clinical Trial Literature. <i>Health Affairs</i> , 2010, 29, 1842-1848.	5.2	27
333	Impact of Medical Therapy on Atheroma Volume Measured by Different Cardiovascular Imaging Modalities. <i>Cardiology Research and Practice</i> , 2010, 2010, 1-13.	1.1	3
334	Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2010, 4, CMC.S5970.	1.8	3
335	Safety of Simvastatin and Goal Attainment for Low-Density Lipoprotein Cholesterol in Sultan Qaboos University Hospital. <i>Oman Medical Journal</i> , 2010, 25, 264-8.	1.0	4
336	The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality. <i>Journal of Lipid Research</i> , 2010, 51, 2384-2393.	4.2	87
337	Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy. <i>Archives of Internal Medicine</i> , 2010, 170, 1032.	3.8	116
338	Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. <i>Journal of Lipid Research</i> , 2010, 51, 755-762.	4.2	33
339	ARBITER 6-HALTS. Does it have the power to settle all matters?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 77-81.	2.1	0
340	Pharmacotherapy of dyslipidemias in the adult population. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3041-3052.	1.8	8
341	Treatment of dyslipidaemia in childhood. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 739-753.	1.8	8
342	Assessing individual cardiac risk using extra-cardiac arterial imaging. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 529-543.	1.5	0
343	Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia. <i>New England Journal of Medicine</i> , 2010, 362, 906-916.	27.0	275

#	ARTICLE	IF	CITATIONS
344	Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 398-404.	2.6	21
345	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. <i>Current Medical Research and Opinion</i> , 2010, 26, 365-375.	1.9	13
346	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
347	Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. <i>Clinical Nephrology</i> , 2010, 74, 282-287.	0.7	7
348	Ezetimibe and recent clinical trials: a look on the bright side. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 511-514.	2.4	5
349	Effects of Statins on the Epicardial Fat Thickness in Patients with Coronary Artery Stenosis Underwent Percutaneous Coronary Intervention: Comparison of Atorvastatin with Simvastatin/Ezetimibe. <i>Journal of Cardiovascular Imaging</i> , 2010, 18, 121.	0.8	82
350	Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. <i>European Heart Journal</i> , 2010, 31, 1633-1639.	2.2	65
351	Arzneiverordnungs-Report 2010. , 2010, , .		41
352	Measuring hsCRPâ€”An Important Part of a Comprehensive Risk Profile or a Clinically Redundant Practice?. <i>PLoS Medicine</i> , 2010, 7, e1000196.	8.4	15
353	Medical Management of Carotid Stenosis. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2010, 22, 18-27.	0.6	9
354	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. <i>European Heart Journal</i> , 2010, 31, 1677-1681.	2.2	64
355	Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 73-85.	1.4	63
356	Biomarkers of Vulnerable Atheromatous Plaques. <i>Advances in Clinical Chemistry</i> , 2010, 50, 1-22.	3.7	16
357	Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 775-779.	1.5	10
358	Raising highly desirable lipoprotein versus lowering deleterious lipoprotein. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 173-176.	3.1	0
359	Carotid Intima-Media Thickness: Knowledge and Application to Everyday Practice. <i>Postgraduate Medicine</i> , 2010, 122, 10-18.	2.0	93
360	Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. <i>Current Medical Research and Opinion</i> , 2010, 26, 737-744.	1.9	1
361	Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. <i>Journal of Lipid Research</i> , 2010, 51, 3289-3298.	4.2	42

#	ARTICLE	IF	CITATIONS
362	Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 189-197.	0.4	7
363	Clinical Update on Nursing Home Medicine: 2010. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 543-566.	2.5	6
364	Secondary stroke prevention. <i>Nature Reviews Neurology</i> , 2010, 6, 477-486.	10.1	27
365	Carotid intima-media thickness for the practicing lipidologist. <i>Journal of Clinical Lipidology</i> , 2010, 4, 24-35.	1.5	31
366	Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis. <i>Journal of Clinical Lipidology</i> , 2010, 4, 346-349.	1.5	21
367	An evaluation of alanine transaminase and creatine kinase elevations with the use of ezetimibe in an ambulatory care setting. <i>Journal of Clinical Lipidology</i> , 2010, 4, 501-507.	1.5	3
368	Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients. <i>Journal of Clinical Lipidology</i> , 2010, 4, 491-500.	1.5	14
369	Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 26-32.	1.6	13
370	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	10.9	42
371	Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia. <i>Clinical Drug Investigation</i> , 2010, 30, 157-166.	2.2	5
372	The role of ezetimibe in the prevention of cardiovascular disease: Where do we stand after ARBITER 6-HALTS. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 295-300.	2.6	7
373	A new paradigm for managing dyslipidemia with combination therapy: laropirant + niacin + simvastatin. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 437-449.	4.1	9
374	An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. <i>American Heart Journal</i> , 2010, 159, 705-709.	2.7	82
375	Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. <i>American Heart Journal</i> , 2010, 160, 701-714.	2.7	79
376	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2010, 160, 1130-1136.e3.	2.7	33
377	Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 277-291.	46.4	127
378	Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. <i>Atherosclerosis</i> , 2010, 209, 189-194.	0.8	250
379	Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007. <i>Atherosclerosis</i> , 2010, 211, 271-277.	0.8	18

#	ARTICLE	IF	CITATIONS
380	Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness. <i>Atherosclerosis</i> , 2010, 212, 571-574.	0.8	21
381	<i>Clinical Pharmacology: Current Topics and Case Studies.</i> , 2010, , .		0
382	Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. <i>Drugs and Aging</i> , 2010, 27, 959-972.	2.7	13
383	Niacin Compared with Ezetimibe. <i>New England Journal of Medicine</i> , 2010, 362, 1046-1048.	27.0	10
384	The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 369-382.	2.2	23
385	Attenuation of Rate of Change in Carotid Intima-Media Thickness by Lipid-Modifying Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 253-263.	2.2	31
386	The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2011, 27, 685-692.	1.9	31
387	Asymmetric Responsiveness of Physician Prescription Behavior to Drug Promotion of Competitive Brands Within an Established Therapeutic Drug Class. <i>Health Marketing Quarterly</i> , 2011, 28, 133-154.	1.0	12
389	End-Point Selection for Acute Heart Failure Trials. <i>Heart Failure Clinics</i> , 2011, 7, 481-495.	2.1	0
390	Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 858-861.	2.8	5
391	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. <i>Cardiology Clinics</i> , 2011, 29, 87-103.	2.2	37
392	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, e16-e94.	2.8	249
393	Carotid Intima-Media Thickness as a Surrogate Endpoint. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2291-2292.	2.8	0
395	Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1068-1076.	2.8	27
396	ACCF/AHA/AMAâ€PCPI 2011 Performance Measures for Adults With Coronary Artery Disease and Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 316-336.	2.8	58
397	Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. <i>Journal of Clinical Lipidology</i> , 2011, 5, 124-132.	1.5	4
398	Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S38-S45.	1.5	120
399	Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. <i>Journal of Clinical Lipidology</i> , 2011, 5, 273-280.	1.5	20

#	ARTICLE	IF	CITATIONS
400	MR Imaging of Carotid Plaque Composition During Lipid-Lowering Therapy. JACC: Cardiovascular Imaging, 2011, 4, 977-986.	5.3	140
401	MR Imaging-Verified Plaque Delipidation With Lipid-Lowering Therapy. JACC: Cardiovascular Imaging, 2011, 4, 987-989.	5.3	6
403	Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2011, 21, 187-203.	5.0	12
404	Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport. Annual Review of Physiology, 2011, 73, 239-259.	13.1	262
405	Guidelines for the Primary Prevention of Stroke. Stroke, 2011, 42, 517-584.	2.0	1,289
407	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 265-272.	4.1	60
409	Emerging Therapies for Atherosclerosis Prevention and Management. Cardiology Clinics, 2011, 29, 123-135.	2.2	8
410	Ezetimibe â€“ a new approach in hypercholesterolemia management. Pharmacological Reports, 2011, 63, 1335-1348.	3.3	37
411	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal, 2011, 161, 418-424.e3.	2.7	35
412	Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and donâ€™t know. Diabetes Research and Clinical Practice, 2011, 94, 1-13.	2.8	17
413	Lipid Metabolism in Treated HIV Infection. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 429-442.	4.7	43
414	Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. International Journal of Cardiology, 2011, 148, 131-138.	1.7	10
415	Fumigaclavine C inhibits tumor necrosis factor Î± production via suppression of toll-like receptor 4 and nuclear factor ÎºB activation in macrophages. Life Sciences, 2011, 89, 235-240.	4.3	27
416	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Current Medical Research and Opinion, 2011, 27, 1119-1129.	1.9	43
417	Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis, 2011, 214, 129-138.	0.8	80
418	Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215, 266-278.	0.8	37
419	The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis, 2011, 218, 156-162.	0.8	74
420	Another clinical evidence straw on the \$4 billion ezetimibe camel's back. Atherosclerosis, 2011, 218, 23-25.	0.8	2

#	ARTICLE	IF	CITATIONS
421	Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. <i>Atherosclerosis</i> , 2011, 217, 308-321.	0.8	43
422	Benefits of lowering cholesterol in chronic kidney disease. <i>Lancet, The</i> , 2011, 378, 1376.	13.7	0
423	Inflammation and the Development of Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 351-358.	2.0	139
424	Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. <i>Archives of Medical Science</i> , 2011, 1, 5-7.	0.9	17
425	Managing residual risk in patients receiving statin therapy. <i>Medical Journal of Australia</i> , 2011, 194, 54-54.	1.7	0
428	Drugs that affect lipid metabolism. <i>Side Effects of Drugs Annual</i> , 2011, 33, 921-934.	0.6	1
429	Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. <i>Journal of Medical Investigation</i> , 2011, 58, 86-94.	0.5	17
430	Treatment of dyslipidemia in the elderly. <i>Journal of Geriatric Cardiology</i> , 2011, 8, 55-64.	0.2	16
431	Ezetimibe and Vascular Endothelial Function. <i>Current Vascular Pharmacology</i> , 2011, 9, 87-98.	1.7	4
432	Mean Common or Mean Maximum Carotid Intima-Media Thickness as Primary Outcome in Lipid-Modifying Intervention Studies. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 946-957.	2.0	18
433	CHALLENGES IN ATHEROSCLEROSIS. , 0, , 62-88.		0
435	Statin/ezetimibe combination therapy: emerging evidence. <i>Current Opinion in Lipidology</i> , 2011, 22, 146-147.	2.7	2
436	Combination therapy for dyslipidemia. <i>Current Opinion in Cardiology</i> , 2011, 26, 420-423.	1.8	6
437	Effect of number of ultrasound examinations on the assessment of carotid intima-media thickness changes over time: the example of the METEOR study. <i>Journal of Hypertension</i> , 2011, 29, 1145-1154.	0.5	8
438	Adjunctive Lipid Lowering Therapy in the Era of Surrogate Endpoints. <i>Cardiology in Review</i> , 2011, 19, 17-22.	1.4	6
439	The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 505-512.	1.9	31
440	Antisense Oligonucleotides for the Treatment of Dyslipidemia. <i>Current Pharmaceutical Design</i> , 2011, 17, 950-960.	1.9	18
441	Lipid Management for the Prevention of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 852-860.	1.9	24

#	ARTICLE	IF	CITATIONS
442	Ezetimibe and Reactive Oxygen Species. <i>Current Vascular Pharmacology</i> , 2011, 9, 109-120.	1.7	10
443	Gene Therapy for Familial Hypercholesterolemia. <i>Current Pharmaceutical Design</i> , 2011, 17, 2575-2591.	1.9	30
444	Atherosclerosis, Degenerative Aortic Stenosis and Statins. <i>Current Drug Targets</i> , 2011, 12, 115-121.	2.1	22
445	Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years. <i>Current Vascular Pharmacology</i> , 2011, 9, 62-86.	1.7	31
446	The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. <i>Clinical Investigation</i> , 2011, 1, 137-144.	0.0	0
447	Controlling lipids after acute coronary syndromes: what is the best strategy?. <i>Clinical Lipidology</i> , 2011, 6, 253-255.	0.4	0
448	Communicating Uncertainties About Prescription Drugs to the Public. <i>Archives of Internal Medicine</i> , 2011, 171, 1463.	3.8	56
450	Dyslipidemia Intervention in Metabolic Syndrome: Emphasis on Improving Lipids and Clinical Event Reduction. <i>American Journal of the Medical Sciences</i> , 2011, 341, 388-393.	1.1	27
451	Use of B-Mode Ultrasound to Examine Preclinical Markers of Atherosclerosis. <i>Journal of Ultrasound in Medicine</i> , 2011, 30, 363-369.	1.7	11
452	Surrogate endpoints in randomized cardiovascular clinical trials. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 411-413.	1.9	14
453	The ezetimibe Jonah: the trials and tribulations of an unlucky drug. <i>International Journal of Clinical Practice</i> , 2011, 65, 1207-1208.	1.7	22
454	HYPOLIPIDEMIC EFFECTS OF ORTANIQUE PEEL POLYMETHOXYLATED FLAVONES IN RATS WITH DIET-INDUCED HYPERCHOLESTEROLEMIA. <i>Journal of Food Biochemistry</i> , 2011, 35, 1555-1560.	2.9	11
455	Anti-inflammatory therapeutics for the treatment of atherosclerosis. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 365-376.	46.4	246
457	The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids. <i>American Journal of Cardiology</i> , 2011, 107, 230-242.	1.6	1
458	Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent. <i>American Journal of Cardiology</i> , 2011, 107, 1571-1574.	1.6	13
459	Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades. <i>American Journal of Cardiology</i> , 2011, 108, 223-226.	1.6	58
460	Carotid Intima-Media Thickness Measurement: A Suitable Alternative for Cardiovascular Risk?. , 2011, , 379-395.		0
461	Toward Clinical Applications of Carotid Ultrasound: Intima-Media Thickness, Plaque Area, and Three-Dimensional Phenotypes. , 2011, , 431-448.		2

#	ARTICLE	IF	CITATIONS
462	Effect of Electronic Prescription on Attainment of Cholesterol Goals. <i>Clinical Cardiology</i> , 2011, 34, 254-260.	1.8	11
463	Emerging options in the treatment of dyslipidemias: a bright future?. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 247-270.	2.4	14
464	Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop. <i>AAPS Journal</i> , 2011, 13, 274-283.	4.4	29
467	Lipid lowering therapy in type 2 diabetes. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 289-296.	1.1	10
473	Intensified Lipid-Lowering Therapy in Coronary Heart Disease: Is the Concept of "the Lower the Better" Evidence Based?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 1-3.	0.9	0
474	Treatment of Risk Factors to Prevent Stroke. <i>Neurotherapeutics</i> , 2011, 8, 463-474.	4.4	20
475	State Variation in AIDS Drug Assistance Program Prescription Drug Coverage for Modifiable Cardiovascular Risk Factors. <i>Journal of General Internal Medicine</i> , 2011, 26, 1426-1433.	2.6	8
477	The new strategy for modulating dyslipidemia: Consideration from updated understanding on high-density lipoprotein. <i>Chinese Journal of Integrative Medicine</i> , 2011, 17, 467-470.	1.6	3
478	Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. <i>Lipids</i> , 2011, 46, 341-348.	1.7	30
479	Statins in Combinations: From ARBITER-6 HALTS to ACCORD "What Works?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 4-8.	4.8	0
480	What Combination Therapy with a Statin, If Any, Would You Recommend?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 12-22.	4.8	18
481	Therapies Targeting Exogenous Cholesterol Uptake: New Insights and Controversies. <i>Current Atherosclerosis Reports</i> , 2011, 13, 95-100.	4.8	8
482	Familial Hypercholesterolemia: Present and Future Management. <i>Current Cardiology Reports</i> , 2011, 13, 527-536.	2.9	40
483	Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). <i>Lipids in Health and Disease</i> , 2011, 10, 94.	3.0	121
484	Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 37.	3.3	46
485	Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. <i>Dialysis and Transplantation</i> , 2011, 40, 148-151.	0.2	0
486	Varespladib: targeting the inflammatory face of atherosclerosis. <i>European Heart Journal</i> , 2011, 32, 923-926.	2.2	7
487	Management of dyslipidemia in HIV-infected patients. <i>Clinical Lipidology</i> , 2011, 6, 447-462.	0.4	28

#	ARTICLE	IF	CITATIONS
488	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	2.2	60
489	Atherosclerosis: Current Status of Prevention and Treatment. International Journal of Angiology, 2011, 20, 213-222.	0.6	25
490	Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease. Expert Opinion on Pharmacotherapy, 2011, 12, 2599-2604.	1.8	5
491	Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. American Journal of Clinical Nutrition, 2011, 93, 941-949.	4.7	33
492	Intestinal sterol transporters and cholesterol absorption inhibition. Current Opinion in Lipidology, 2011, 22, 467-478.	2.7	24
493	Dyslipidemia Management. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 1242-1254.	0.8	1
494	Carotid intima-media thickness and cardiovascular risk. Future Cardiology, 2011, 7, 173-182.	1.2	5
495	Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of Lipid Research, 2011, 52, 679-687.	4.2	45
496	Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters. Clinical Medicine Insights: Cardiology, 2011, 5, CMC.S7601.	1.8	6
497	The ezetimibe controversy: implications for clinical practice. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 199-208.	2.1	14
498	ACCF/AHA/AMAâ€“PCPI 2011 Performance Measures for Adults With Coronary Artery Disease and Hypertension. Circulation, 2011, 124, 248-270.	1.6	123
499	Imaging Biomarkers in Atherosclerosis Trials. Circulation: Cardiovascular Imaging, 2011, 4, 319-333.	2.6	63
500	Squalene Synthase Inhibitor Lapaquistat Acetate. Circulation, 2011, 123, 1925-1928.	1.6	21
501	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Circulation, 2011, 124, e54-130.	1.6	100
502	The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 664-678.	4.5	25
503	Squalene monooxygenase â€“ a target for hypercholesterolemic therapy. Biological Chemistry, 2011, 392, 1053-1075.	2.5	40
504	Hyperlipidemia in Primary Care. , 2011, , .		2
505	Significance of LDL-C lowering therapy in diabetic patients. Clinical Lipidology, 2011, 6, 389-399.	0.4	4

#	ARTICLE	IF	CITATIONS
506	Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice. Current Pharmaceutical Design, 2011, 17, 4132-4146.	1.9	47
507	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Stroke, 2011, 42, e464-540.	2.0	162
508	Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy, 2011, 9, 131-145.	1.5	14
509	Atlas of Atherosclerosis and Metabolic Syndrome. , 2011, , .		5
511	Arterial Retention of Remnant Lipoproteins Ex Vivo Is Increased in Insulin Resistance Because of Increased Arterial Biglycan and Production of Cholesterol-Rich Atherogenic Particles That Can Be Improved by Ezetimibe in the JCR:LA-cp Rat. Journal of the American Heart Association, 2012, 1, e003434.	3.7	17
513	Panel discussion 2. Clinical Trials, 2012, 9, 66-79.	1.6	0
514	CKD, Plasma Lipids, and Common Carotid Intima-Media Thickness: Results from the Multi-Ethnic Study of Atherosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1777-1785.	4.5	28
515	The Importance of Clinical Trial Data Sharing. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 238-240.	2.2	83
516	LDL lowering in peripheral arterial disease:are there benefits beyond reducing cardiovascular morbidity and mortality?. Clinical Lipidology, 2012, 7, 141-149.	0.4	9
517	Sample size requirements in trials using repeated measurements and the impact of trial design. Current Medical Research and Opinion, 2012, 28, 681-688.	1.9	9
518	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology, 2012, 8, 813-817.	1.2	3
519	Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endothelial Function. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 357-365.	2.0	25
520	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. European Heart Journal, 2012, 33, 183-190.	2.2	149
521	Antibodies to PCSK9. Circulation Research, 2012, 111, 274-277.	4.5	14
522	Clinical Management Considerations for Dyslipidemia in HIV-Infected Individuals. Postgraduate Medicine, 2012, 124, 31-40.	2.0	2
523	Cardiology in Family Practice. , 2012, , .		3
524	Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 65-71.	2.0	21
525	Carotid intima-media thickness and the prediction of vascular events. Vascular Medicine, 2012, 17, 239-248.	1.5	47

#	ARTICLE	IF	CITATIONS
526	The Use of Combination Lipid Therapy in a County Health System. <i>Journal of Pharmacy Technology</i> , 2012, 28, 227-233.	1.0	0
527	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	1.7	2
528	Metabolic Syndrome: Definition and Therapeutic Implications. <i>Postgraduate Medicine</i> , 2012, 124, 21-30.	2.0	137
529	Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. <i>European Heart Journal</i> , 2012, 33, 2939-2945.	2.2	39
530	Serendipity of post-hoc surrogate marker research. <i>European Heart Journal</i> , 2012, 33, 2897-2898.	2.2	1
531	Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 506-513.	4.7	38
533	Warnings Without Guidance. <i>Medical Care</i> , 2012, 50, 479-484.	2.4	14
534	An epidemic of coronary heart disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 509-518.	0.5	15
535	Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?. <i>Diabetes Management</i> , 2012, 2, 65-74.	0.5	1
536	Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -. <i>Circulation Journal</i> , 2012, 76, 176-183.	1.6	67
537	Ezetimibe Improves Endothelial Function and Inhibits Rho-Kinase Activity Associated With Inhibition of Cholesterol Absorption in Humans. <i>Circulation Journal</i> , 2012, 76, 2023-2030.	1.6	29
538	How to Use Ezetimibe as an Anti-Atherogenic Agent via Inhibition of Rho-Kinase. <i>Circulation Journal</i> , 2012, 76, 1836-1837.	1.6	4
539	Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2012, 59, 1077-1084.	1.6	2
540	Inhibition of PCSK9 in familial hypercholesterolaemia. <i>Lancet, The</i> , 2012, 380, 6-7.	13.7	5
541	Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 1-17.	6.1	16
542	Casting a shadow on liver X receptor-mediated atheroprotection: is LXR ² to blame?. <i>Journal of Internal Medicine</i> , 2012, 272, 449-451.	6.0	1
543	Physiological and Laboratory Markers of Drug Effect. , 2012, , 309-325.		0
544	The Future of Conflicts of Interest: A Call for Professional Standards. <i>Journal of Law, Medicine and Ethics</i> , 2012, 40, 441-451.	0.9	33

#	ARTICLE	IF	CITATIONS
545	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. Cardiovascular Drugs and Therapy, 2012, 26, 349-358.	2.6	14
546	Inhibition of Cholesterol Absorption: Targeting the Intestine. Pharmaceutical Research, 2012, 29, 3235-3250.	3.5	15
547	Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis, 2012, 220, 189-193.	0.8	34
548	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis, 2012, 223, 251-261.	0.8	203
549	Ultrasound and radiology surrogate endpoints in pharmacological studies. Atherosclerosis, 2012, 224, 12-24.	0.8	7
550	Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis. Canadian Journal of Cardiology, 2012, 28, 687-692.	1.7	2
552	A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology, 2012, 60, 12-17.	1.9	33
553	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 2012, 18, 1-78.	2.1	386
554	Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?. Expert Review of Cardiovascular Therapy, 2012, 10, 675-677.	1.5	0
555	Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. American Journal of Cardiovascular Drugs, 2012, 12, 49-56.	2.2	12
556	The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. Clinical Pharmacology and Therapeutics, 2012, 91, 685-691.	4.7	10
557	Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. Expert Opinion on Pharmacotherapy, 2012, 13, 1985-1988.	1.8	14
558	The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundamental and Clinical Pharmacology, 2012, 26, 424-431.	1.9	18
559	Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte II). Clínica e Investigación En Arteriosclerosis, 2012, 24, 40-52.	0.8	3
560	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology, 2012, 6, 180-191.	1.5	19
561	Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe. Current Therapeutic Research, 2012, 73, 1-15.	1.2	18
562	Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia—Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia. Current Therapeutic Research, 2012, 73, 16-40.	1.2	11
563	Maximum carotid artery wall thickness and risk factors in a young primary prevention population. Brain and Behavior, 2012, 2, 590-594.	2.2	0

#	ARTICLE	IF	CITATIONS
564	A Case Study of Singleâ€ Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia. ChemMedChem, 2012, 7, 1882-1894.	3.2	5
565	Differential effects of the changes of LDL cholesterol and systolic blood pressure on the risk of carotid artery atherosclerosis. BMC Cardiovascular Disorders, 2012, 12, 66.	1.7	8
566	Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy. Annals of Pharmacotherapy, 2012, 46, 1368-1381.	1.9	28
568	Drug Therapy of Hypercholesterolaemia in Children and Adolescents. Drugs, 2012, 72, 759-772.	10.9	33
569	LDL Cholesterol: The Lower the Better. Medical Clinics of North America, 2012, 96, 13-26.	2.5	73
570	The buck stops here. American Journal of Orthodontics and Dentofacial Orthopedics, 2012, 142, 430.	1.7	0
571	Novel LDL-oriented pharmacotherapeutical strategies. Pharmacological Research, 2012, 65, 402-410.	7.1	3
572	Extensive or Restricted Ultrasound Protocols to Measure Carotid Intima-Media Thickness: Analysis of Completeness Rates and Impact on Observed Rates of Change Over Time. Journal of the American Society of Echocardiography, 2012, 25, 91-100.	2.8	24
573	Current imaging modalities for atherosclerosis. Expert Review of Cardiovascular Therapy, 2012, 10, 457-471.	1.5	7
575	Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. Journal of Cardiology, 2012, 60, 111-118.	1.9	12
576	Role of Lipotoxicity in Endothelial Dysfunction. Heart Failure Clinics, 2012, 8, 589-607.	2.1	94
577	Dyslipidemia. , 2012, , 159-178.		0
578	The â€ Mevalonate hypothesisâ€ a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids in Health and Disease, 2012, 11, 149.	3.0	12
579	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	2.3	169
580	Guidelines for the Management of Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2012, 19, 1043-1060.	2.0	157
581	Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review. International Journal of Nephrology and Renovascular Disease, 2012, 5, 165.	1.8	3
582	The Heart and Medicine: Exploring the Interconnectedness of Cardiometabolic-related Concerns through a Systems Biology Approach. Global Advances in Health and Medicine, 2012, 1, 38-45.	1.6	0
583	A tool for evaluating the potential for cost-effective outcomes measurement. International Journal of General Medicine, 2012, 5, 365.	1.8	1

#	ARTICLE	IF	CITATIONS
584	Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. <i>Vascular Health and Risk Management</i> , 2012, 8, 437.	2.3	13
585	Cost effective prescribing in cardiovascular disease. <i>Practice Nursing</i> , 2012, 23, 488-492.	0.1	0
586	Is the Carotid Intima-Media Thickness Really a Good Surrogate Marker of Atherosclerosis?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 680-690.	2.0	22
587	Challenge of Surrogate Endpoints. <i>Southern Medical Journal</i> , 2012, 105, 156-160.	0.7	4
588	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. <i>Vascular Health and Risk Management</i> , 2012, 8, 651.	2.3	43
589	Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 1095-1101.	1.5	11
590	The ezetimibe controversy “can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?”. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1469-1480.	1.8	10
591	Do clinical and experimental investigations support an antiatherogenic role for dietary phytosterols/stanols?. <i>IUBMB Life</i> , 2012, 64, 296-306.	3.4	14
592	The Role of Intravascular Ultrasound in the Determination of Progression and Regression of Coronary Artery Disease. <i>Current Atherosclerosis Reports</i> , 2012, 14, 175-185.	4.8	10
593	Does Cardiovascular Ultrasound Have a Role in Assessment of Cardiovascular Risk in Asymptomatic Persons?. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 164-175.	2.0	0
594	The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. <i>Journal of Internal Medicine</i> , 2012, 271, 32-42.	6.0	41
595	Usefulness of Cardiovascular Magnetic Resonance Imaging of the Superficial Femoral Artery for Screening Patients With Diabetes Mellitus for Atherosclerosis. <i>American Journal of Cardiology</i> , 2012, 110, 50-56.	1.6	17
596	Recent Clinical Studies of the Effects of Lipid-Modifying Therapies. <i>American Journal of Cardiology</i> , 2012, 110, 15A-26A.	1.6	36
597	Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. <i>Journal of Internal Medicine</i> , 2012, 271, 247-256.	6.0	25
598	LXR ¹ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile. <i>Journal of Internal Medicine</i> , 2012, 272, 452-464.	6.0	24
599	Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. <i>International Journal of Clinical Practice</i> , 2012, 66, 800-812.	1.7	17
600	LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. <i>Journal of Renal Care</i> , 2012, 38, 138-146.	1.2	5
601	Surrogate End Points in Secondary Analyses of Cardiovascular Trials. <i>Progress in Cardiovascular Diseases</i> , 2012, 54, 343-350.	3.1	8

#	ARTICLE	IF	CITATIONS
602	Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: Impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. <i>Journal of Cardiology</i> , 2012, 59, 50-56.	1.9	42
603	Therapeutic strategies to deplete macrophages in atherosclerotic plaques. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 246-263.	2.4	23
604	One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 49-58.	2.7	31
605	Ethical Issues in New Drug Prescribing. <i>Journal of Bioethical Inquiry</i> , 2012, 9, 77-83.	1.5	4
606	Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. <i>Lipids in Health and Disease</i> , 2013, 12, 9.	3.0	21
607	Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy. <i>Journal of Neuroinflammation</i> , 2013, 10, 78.	7.2	33
609	Medical Management of Stable Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 313.	4.8	6
610	Challenges in the Pharmacologic Management of Obesity and Secondary Dyslipidemia in Children and Adolescents. <i>Paediatric Drugs</i> , 2013, 15, 335-342.	3.1	20
611	The Changing Face of Vascular Interventional Radiology: The Future Role of Pharmacotherapies and Molecular Imaging. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 904-912.	2.0	2
612	Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. <i>Drugs</i> , 2013, 73, 327-339.	10.9	190
613	Pharmacotherapies for lipid modification: beyond the statins. <i>Nature Reviews Cardiology</i> , 2013, 10, 560-570.	13.7	35
614	The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome. <i>Cardiology</i> , 2013, 125, 74-77.	1.4	15
615	End Points for Comparative Effectiveness Research in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 15-28.	2.1	18
616	All at sea: new lipid-lowering drug trials continue to disappoint. <i>International Journal of Clinical Practice</i> , 2013, 67, 595-598.	1.7	3
617	Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options. <i>Atherosclerosis</i> , 2013, 230, 381-389.	0.8	59
618	Icosapent Ethyl for Treatment of Elevated Triglyceride Levels. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1517-1523.	1.9	12
619	Clinical Relevance of Target Identity and Biology. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1164-1185.	2.6	7
620	Assessment of Low-Density Lipoprotein Targets. <i>Angiology</i> , 2013, 64, 411-416.	1.8	11

#	ARTICLE	IF	CITATIONS
621	Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 401-411.	2.0	28
623	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology, 2013, 8, 329-344.	0.4	5
624	Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology, 2013, 10, 648-661.	13.7	92
625	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. Therapeutic Apheresis and Dialysis, 2013, 17, 125-129.	0.9	1
626	Target cardiovascular risk rather than cholesterol concentration. BMJ, The, 2013, 347, f7110-f7110.	6.0	13
627	Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis, 2013, 228, 1-11.	0.8	239
628	Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis, 2013, 231, 411-420.	0.8	14
629	The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin. International Journal of Cardiology, 2013, 167, 2088-2091.	1.7	4
631	PANACEA or much a do about nothing: Effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. Atherosclerosis, 2013, 227, 32-34.	0.8	0
632	Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality. American Journal of Cardiology, 2013, 111, 532-539.	1.6	15
633	A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings, 2013, 88, 790-798.	3.0	300
634	HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe?. Atherosclerosis, 2013, 229, 449-450.	0.8	12
635	Assessment of subclinical atherosclerosis and intraplaque neovascularization using quantitative contrast-enhanced ultrasound in patients with familial hypercholesterolemia. Atherosclerosis, 2013, 231, 107-113.	0.8	31
636	Impact of Adding Ezetimibe to Statin to Achieve Low-Density Lipoprotein Cholesterol Goal (from the Tj ETQq1 1 0.784314 rgBT /Overlo American Journal of Cardiology, 2013, 111, 1557-1562.	1.6	10
637	Atherosclerosis: lessons from LXR and the intestine. Trends in Endocrinology and Metabolism, 2013, 24, 120-128.	7.1	57
639	A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. Drugs, 2013, 73, 1025-1054.	10.9	30
640	Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sciences, 2013, 92, 845-851.	4.3	21
641	Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes. Expert Review of Cardiovascular Therapy, 2013, 11, 327-342.	1.5	29

#	ARTICLE	IF	CITATIONS
642	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. <i>Current Cardiology Reports</i> , 2013, 15, 391.	2.9	9
643	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 631-642.	3.1	140
644	Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-Density Lipoprotein Cholesterol Lowering. <i>Pharmacotherapy</i> , 2013, 33, 447-460.	2.6	5
645	Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia. <i>Clinical Therapeutics</i> , 2013, 35, 450-460.	2.5	1
646	Traditional Risk Factors Are Not Major Contributors to the Variance in Carotid Intima-Media Thickness. <i>Stroke</i> , 2013, 44, 2101-2108.	2.0	75
647	Carotid Intima-Media Thickness Testing as an Asymptomatic Cardiovascular Disease Identifier and Method for Making Therapeutic Decisions. <i>Postgraduate Medicine</i> , 2013, 125, 108-123.	2.0	22
648	Lipid disorders. , 2013, , 68-77.		1
649	Diagnosis and treatment of familial hypercholesterolaemia. <i>European Heart Journal</i> , 2013, 34, 962-971.	2.2	212
650	Selective thyroid hormone receptor modulators. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 211.	0.4	15
651	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	2.0	7
652	Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 5-12.	2.0	32
653	Current challenges in the management of patients with familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 217-229.	0.4	0
654	An Observational Study of Ezetimibe in Cardiac Transplant Recipients Receiving Calcineurin Inhibitors. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1457-1462.	1.9	10
655	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	23
656	Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. <i>Journal of Lipid Research</i> , 2013, 54, 3189-3197.	4.2	12
657	Imaging biomarkers to track subclinical atherosclerosis in heterozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 231-242.	0.4	2
658	Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 of Preventive Cardiology, 2013, 20, 1069-1079.	1.8	21
659	Surrogate Outcomes in Clinical Trials. <i>JAMA Internal Medicine</i> , 2013, 173, 611.	5.1	109

#	ARTICLE	IF	CITATIONS
660	Results From a Carotid Intima-Media Thickness Trial as a Decision Tool for Launching a Large-Scale Morbidity and Mortality Trial. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 20-25.	2.6	23
661	Contemporary Approaches for Evidence-Based Pharmacotherapy. <i>Journal of Pharmacy Practice</i> , 2013, 26, 95-102.	1.0	1
662	Differences in Action of Atorvastatin and Ezetimibe in Lowering Low-Density Lipoprotein Cholesterol and Effect on Endothelial Function. <i>Circulation Journal</i> , 2013, 77, 1791-1798.	1.6	22
663	Optimal use of lipid-altering therapy: guidelines versus evidence. <i>Clinical Lipidology</i> , 2013, 8, 269-272.	0.4	0
664	GW24-e1865â€¦Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. <i>Heart</i> , 2013, 99, A126.2-A126.	2.9	0
666	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. <i>Vascular Health and Risk Management</i> , 2013, 9, 671.	2.3	28
667	Effects of Rosuvastatin vs. Simvastatin/ezetimibe on Arterial Wall Stiffness in Patients with Coronary Artery Disease. <i>Internal Medicine</i> , 2013, 52, 2715-2719.	0.7	9
669	Intestinal and Hepatic Niemann-Pick C1-Like 1. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 240.	4.7	27
670	Statins and regression of organ damage. <i>Italian Journal of Medicine</i> , 2013, , 227-233.	0.3	0
671	Carotid Intima-Media Thickness Studies: Study Design and Data Analysis. <i>Journal of Stroke</i> , 2013, 15, 38.	3.2	23
672	Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 139-149.	2.2	88
673	A Markov Model of the Cost-Effectiveness of Pharmacist Care for Diabetes in Prevention of Cardiovascular Diseases: Evidence from Kaiser Permanente Northern California. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 102-114.	2.2	67
674	Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia: a Randomized Control Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 245-256.	2.0	8
675	Clinical management of familial hypercholesterolemia: new insights from international guidelines and recent studies. <i>Neurology International</i> , 2014, 4, .	0.5	0
676	Add-On Effect of Probucol in Atherosclerotic, Cholesterol-Fed Rabbits Treated with Atorvastatin. <i>PLoS ONE</i> , 2014, 9, e96929.	2.5	15
677	Common Carotid Intima Media Thickness and Ankle-Brachial Pressure Index Correlate with Local but Not Global Atheroma Burden: A Cross Sectional Study Using Whole Body Magnetic Resonance Angiography. <i>PLoS ONE</i> , 2014, 9, e99190.	2.5	19
678	Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. <i>Genetics and Molecular Research</i> , 2014, 13, 2377-2384.	0.2	19
679	Dyslipidemia in women: etiology and management. <i>International Journal of Women's Health</i> , 2014, 6, 185.	2.6	57

#	ARTICLE	IF	CITATIONS
680	Current Treatment of Familial Hypercholesterolaemia. <i>European Cardiology Review</i> , 2014, 9, 76.	2.2	16
681	Are the New Guidelines for the Use of Lipid-Lowering Agents Sound, and Should Their Adoption Be Encouraged?. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 246-9.	0.1	4
682	Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe. <i>Korean Circulation Journal</i> , 2014, 44, 227.	1.9	6
683	Effect of plant sterols compared with ezetimibe on oxidative stress in patients treated with statins. <i>Journal of Functional Foods</i> , 2014, 10, 178-186.	3.4	2
684	Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1122-1134.	3.4	33
685	Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf. <i>Current Medical Research and Opinion</i> , 2014, 30, 2429-2435.	1.9	13
686	Consensus statement on management of dyslipidemia in Indian subjects. <i>Indian Heart Journal</i> , 2014, 66, S1-S51.	0.5	47
687	Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigm. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 161-165.	1.5	1
688	Anti-Inflammatory Activity of Ezetimibe by Regulating NF- κ B/MAPK Pathway in THP-1 Macrophages. <i>Pharmacology</i> , 2014, 93, 69-75.	2.2	22
689	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
690	Individualized cardiovascular risk assessment by cardiovascular magnetic resonance. <i>Future Cardiology</i> , 2014, 10, 273-289.	1.2	20
691	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 554-561.	1.5	128
692	High-Dose Simvastatin Exhibits Enhanced Lipid-Lowering Effects Relative to Simvastatin/Ezetimibe Combination Therapy. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 955-964.	5.1	13
693	Cholesterol Treatment Patterns and Cardiovascular Clinical Outcomes Associated with Colesevelam HCl and Ezetimibe. <i>Drugs and Aging</i> , 2014, 31, 683-694.	2.7	4
694	Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. <i>International Journal of Cardiology</i> , 2014, 177, 152-160.	1.7	7
695	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1215-1230.	6.9	11
696	Despite Increased Use And Sales Of Statins In India, Per Capita Prescription Rates Remain Far Below High-Income Countries. <i>Health Affairs</i> , 2014, 33, 273-282.	5.2	40
697	Combined Phytosterol and Fish Oil Therapy for Lipid Lowering and Cardiovascular Health. , 2014, , 437-463.		2

#	ARTICLE	IF	CITATIONS
698	Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. <i>Cardiology in the Young</i> , 2014, 24, 437-441.	0.8	13
699	Efficacy and safety of ezetimibe plus atorvastatin therapy. <i>Clinical Lipidology</i> , 2014, 9, 441-470.	0.4	7
700	Familial hypercholesterolaemia. <i>Current Opinion in Cardiology</i> , 2014, 29, 381-388.	1.8	18
701	Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. <i>JAMA Internal Medicine</i> , 2014, 174, 1486.	5.1	20
702	Familial Hypercholesterolemia. <i>Deutsches A&#x0308;rztblatt International</i> , 2014, 111, 523-9.	0.9	62
703	Familial hypercholesterolemia: A review. <i>Annals of Pediatric Cardiology</i> , 2014, 7, 107.	0.5	59
704	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. <i>Annales De Cardiologie Et D'Angiologie</i> , 2014, 63, 222-227.	0.6	7
705	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
706	Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. <i>American Heart Journal</i> , 2014, 167, 683-689.	2.7	16
707	Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome. <i>IJC Metabolic & Endocrine</i> , 2014, 3, 8-13.	0.5	23
708	Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis. <i>Phytotherapy Research</i> , 2014, 28, 633-642.	5.8	252
709	Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia. <i>Diabetology International</i> , 2014, 5, 175-180.	1.4	0
710	Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2014, 8, 18-28.	1.5	34
711	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	6.8	149
712	Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies. <i>Current Atherosclerosis Reports</i> , 2014, 16, 390.	4.8	5
713	The Saturated Fat, Cholesterol, and Statin Controversy A Commentary. <i>Journal of the American College of Nutrition</i> , 2014, 33, 79-88.	1.8	9
714	The Antithrombotic Effects of Statins. <i>Annual Review of Medicine</i> , 2014, 65, 433-445.	12.2	41
716	Medical Imaging in Clinical Trials. , 2014, , .		19

#	ARTICLE	IF	CITATIONS
717	Drugs that affect lipid metabolism. Side Effects of Drugs Annual, 2014, , 807-819.	0.6	0
718	Cardiovascular complications after transplantation: Treatment options in solid organ recipients. Transplantation Reviews, 2014, 28, 47-55.	2.9	30
719	Secondary stroke prevention. Lancet Neurology, The, 2014, 13, 178-194.	10.2	227
720	Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs, 2014, 19, 471-488.	2.4	5
721	Guidelines for the Primary Prevention of Stroke. Stroke, 2014, 45, 3754-3832.	2.0	1,621
722	Inactivating Mutations in <i>NPC1L1</i> and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082.	27.0	386
723	The thyroid receptor β^2 modulator GC-1 reduces atherosclerosis in ApoE deficient mice. Atherosclerosis, 2014, 237, 544-554.	0.8	15
724	Carotid Intima-Media Thickness and Plaque in Cardiovascular Risk Assessment. JACC: Cardiovascular Imaging, 2014, 7, 1025-1038.	5.3	455
725	Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?. Clinical Pharmacology and Therapeutics, 2014, 96, 192-205.	4.7	20
726	Impact of Drug Policy on Regional Trends in Ezetimibe Use. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 589-596.	2.2	8
727	Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. Journal of the American Society of Hypertension, 2014, 8, 715-723.	2.3	8
728	The Effect of Simvastatin–Ezetimibe Combination Therapy on Adipose Tissue Hormones and Systemic Inflammation in Patients with Isolated Hypercholesterolemia. Cardiovascular Therapeutics, 2014, 32, 40-46.	2.5	37
729	Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart, 2014, 100, 1085-1092.	2.9	74
730	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. Journal of Clinical Lipidology, 2014, 8, 373-380.	1.5	2
731	LDL cholesterol: controversies and future therapeutic directions. Lancet, The, 2014, 384, 607-617.	13.7	229
732	Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis, 2014, 237, 319-335.	0.8	39
733	Increasing spatial resolution of 3T MRI scanning improves reproducibility of carotid arterial wall dimension measurements. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 219-226.	2.0	21
734	Risks and Benefits of Statin Use in Young People with Type 1 Diabetes. Current Diabetes Reports, 2014, 14, 499.	4.2	11

#	ARTICLE	IF	CITATIONS
735	Effects of Ezetimibe on Endothelial Progenitor Cells and Microparticles in High-Risk Patients. <i>Cell Biochemistry and Biophysics</i> , 2014, 70, 687-696.	1.8	21
736	Iron and Atherosclerosis: Nailing Down a Novel Target with Magnetic Resonance. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 533-542.	2.4	12
737	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <i>European Heart Journal</i> , 2014, 35, 1996-2000.	2.2	34
738	Low-Density Lipoprotein Levels and Not Mutation Status Predict Intima-Media Thickness in Familial Hypercholesterolemia. <i>Annals of Vascular Surgery</i> , 2014, 28, 421-426.	0.9	6
739	Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study. <i>Journal of Cardiology</i> , 2014, 64, 501-507.	1.9	8
740	A systematic review of the time course of atherosclerotic plaque regression. <i>Atherosclerosis</i> , 2014, 234, 75-84.	0.8	55
741	High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. <i>Heart</i> , 2014, 100, 867-872.	2.9	22
742	Historical perspectives on the impact of n-3 and n-6 nutrients on health. <i>Progress in Lipid Research</i> , 2014, 55, 17-29.	11.6	113
743	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 369-385.	4.7	32
744	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	2.7	93
745	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 387-403.	4.7	30
746	The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia. <i>Pharmacological Reports</i> , 2014, 66, 442-447.	3.3	8
747	Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work. <i>Pharmacotherapy</i> , 2014, 34, 961-972.	2.6	7
748	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	1.5	6
749	Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction. <i>Circulation Journal</i> , 2014, 79, 161-168.	1.6	37
751	Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy. <i>Annals of Internal Medicine</i> , 2014, 160, 468.	3.9	57
752	Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. <i>Clinical Cardiology</i> , 2015, 38, 763-769.	1.8	12
753	Improving the odds: ezetimibe and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015, 69, 390-395.	1.7	2

#	ARTICLE	IF	CITATIONS
754	Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis. <i>Lipids in Health and Disease</i> , 2015, 14, 140.	3.0	8
755	Importance of early recognition of heterozygous familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 298-303.	2.7	7
756	The hinterland of familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 475-483.	2.7	6
757	Has IMPROVE-IT improved cardiovascular outcome?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2015, 45, 215-217.	0.6	0
758	Combination pharmacotherapy in lipid management. <i>Journal of the Korean Medical Association</i> , 2015, 58, 745.	0.3	0
759	Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease. <i>International Heart Journal</i> , 2015, 56, 278-285.	1.0	49
760	Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0124587.	2.5	27
761	Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. <i>PLoS ONE</i> , 2015, 10, e0142430.	2.5	38
762	Hypercholesterolemia in Childhood. , 0, , .		2
763	Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2015, 166, 1377-1384.e3.	1.8	56
764	Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction. <i>Cardiovascular Medicine</i> , 2015, , 461-504.	0.0	1
765	Cholesterol Absorption Inhibitor Ezetimibe: Riskâ€“Benefits and Role in Treating Dyslipidemias. <i>Contemporary Endocrinology</i> , 2015, , 465-481.	0.1	0
766	Twenty-five years of statins: where do we go from here?. <i>Clinical Lipidology</i> , 2015, 10, 33-45.	0.4	2
767	The past, present and future of lipid-lowering therapy. <i>Clinical Lipidology</i> , 2015, 10, 481-498.	0.4	6
768	Acyltransferase inhibitors: a patent review (2010â€“present). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 145-158.	5.0	38
769	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 1-21.	1.3	26
770	Ezetimibe Use Remains Common Among Medicalâ€“Inpatients. <i>American Journal of Medicine</i> , 2015, 128, 193-195.	1.5	2
771	Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2015, 49, 484-493.	1.9	9

#	ARTICLE	IF	CITATIONS
772	Lipid Management. , 2015, , .		1
773	Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology, 2015, 12, 565-575.	13.7	101
774	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 495-507.	2.8	352
775	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Journal of Clinical Lipidology, 2015, 9, 496-497.	1.5	1
778	Statins and Ezetimibe. , 2015, , 25-36.		1
779	Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. European Heart Journal, 2015, 36, 1601-1608.	2.2	59
780	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs, 2015, 75, 1201-1228.	10.9	18
781	IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. Atherosclerosis, 2015, 241, 498-501.	0.8	26
782	The Effect of Atorvastatin and Atorvastatin-Ezetimibe Combination Therapy on Androgen Production in Hyperandrogenic Women with Elevated Cholesterol Levels. Experimental and Clinical Endocrinology and Diabetes, 2015, 123, 75-79.	1.2	5
783	Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sciences, 2015, 132, 77-84.	4.3	43
784	Developing Medicines That Mimic the Natural Successes of the Human Genome. Journal of the American College of Cardiology, 2015, 65, 1562-1566.	2.8	39
785	Role for Combination Therapy in Diabetic Dyslipidemia. Current Cardiology Reports, 2015, 17, 32.	2.9	26
787	Novel insights on the treatment of hypercholesterolemia. Expert Review of Endocrinology and Metabolism, 2015, 10, 269-271.	2.4	2
788	Using inactivating mutations to provide insight into drug action. Genome Medicine, 2015, 7, 7.	8.2	2
789	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet, The, 2015, 385, 2153-2161.	13.7	92
790	Effects of Simvastatin and Ezetimibe in Lowering Low-Density Lipoprotein Cholesterol in Subjects with Type 1 and Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders, 2015, 13, 84-90.	1.3	13
791	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 191, 138-148.	1.7	39
792	Ezetimibe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e13-5.	2.4	15

#	ARTICLE	IF	CITATIONS
793	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2015, 16, 1255-1262.	1.8	15
794	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	1.7	28
795	Medical Management of Serum Lipids and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 39-55.	0.0	0
796	Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. Journal of Cardiology, 2015, 66, 353-358.	1.9	11
797	Statins and Aspirin: Do They Really Work in Women?. American Journal of Cardiovascular Drugs, 2015, 15, 151-162.	2.2	1
798	Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. Atherosclerosis, 2015, 242, 340-345.	0.8	14
799	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. Current Cardiology Reports, 2015, 17, 109.	2.9	28
800	Dyslipidemia in Obesity. , 2015, , 1-18.		1
801	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1864-1872.	2.8	24
802	Genetic considerations in the treatment of familial hypercholesterolemia. Clinical Lipidology, 2015, 10, 387-403.	0.4	2
803	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1873-1875.	2.8	4
804	Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation, 2015, 132, 1825-1833.	1.6	44
805	Lipid-Lowering Therapy and Apheresis: Indications and Outcomes. , 2015, , 143-152.		0
806	Statins and Mipomersen: Mechanisms of Action and Patient Tolerability. , 2015, , 73-86.		1
807	Safety and efficacy of ezetimibe: A meta-analysis. International Journal of Cardiology, 2015, 201, 247-252.	1.7	70
808	Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome. Evidence-Based Medicine, 2015, 20, 176-176.	0.6	1
809	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circulation: Cardiovascular Genetics, 2015, 8, 688-695.	5.1	6
810	Clinical imaging in anti-atherosclerosis drug development. Drug Discovery Today, 2015, 20, 1317-1327.	6.4	4

#	ARTICLE	IF	CITATIONS
811	Antilipidemic Drug Therapy Today and in the Future. Handbook of Experimental Pharmacology, 2015, 233, 373-435.	1.8	5
812	Fixed-dose combination ezetimibe+atorvastatin lowers <sc>LDL</sc>-equivalent to co-administered components in randomized trials: use of a dose-response model. Fundamental and Clinical Pharmacology, 2015, 29, 209-218.	1.9	6
813	Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics, 2015, 52, 71-79.	3.2	52
814	Annexin A5 haplotypes in familial hypercholesterolemia: Lack of association with carotid intima-media thickness and cardiovascular disease risk. Atherosclerosis, 2015, 238, 195-200.	0.8	8
815	Management of Extracranial Carotid Artery Disease. Cardiology Clinics, 2015, 33, 1-35.	2.2	68
816	Understanding Medical Literature. Hospital Medicine Clinics, 2015, 4, 106-127.	0.2	0
817	Omega 3 Fatty Acids Counterbalance Actions of Omega-6 Fatty Acids. , 2016, , 87-100.		1
818	The Value of Subclinical Carotid Atherosclerosis for Primary Prevention of Cardiovascular Diseases. Review of the Main International Studies. Rational Pharmacotherapy in Cardiology, 2016, 12, 558-566.	0.8	3
819	Diabetes Mellitus and Intestinal Niemann-Pick C1-Like 1 Gene Expression. , 2016, , 277-290.		2
820	Carotid Intima-media Thickness Measurements. Chinese Medical Journal, 2016, 129, 215-226.	2.3	59
821	IMPROVE-IT. Current Opinion in Cardiology, 2016, 31, 426-433.	1.8	16
822	Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice. Journal of Vascular Surgery, 2016, 64, 1112-1120.e1.	1.1	9
824	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Human Genetics, 2016, 135, 453-467.	3.8	15
825	Histological evaluation disqualifies IMT and calcification scores as surrogates for grading coronary and aortic atherosclerosis. International Journal of Cardiology, 2016, 224, 328-334.	1.7	19
826	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Journal, 2016, 182, 89-96.	2.7	15
827	The Effect of Ezetimibe/Statin Combination and High-Dose Statin Therapy on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis and Cardiovascular Disease: A Pilot Study. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 577-581.	1.2	3
828	Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROSuvastatin and eZEtimibe). Cardiovascular Therapeutics, 2016, 34, 371-382.	2.5	45
830	Diet did not die. Just another diet study or?. Atherosclerosis, 2016, 251, 534-535.	0.8	1

#	ARTICLE	IF	CITATIONS
831	Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system. American Journal of Health-System Pharmacy, 2016, 73, S141-S147.	1.0	0
832	Cholesterol-absorbed in thought. Current Opinion in Lipidology, 2016, 27, 202-203.	2.7	0
833	My Approach to the Patient With Familial Hypercholesterolemia. Mayo Clinic Proceedings, 2016, 91, 770-786.	3.0	35
834	Might ezetimibe be considered an expensive placebo?. International Journal of Cardiology, 2016, 207, 48-49.	1.7	1
835	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Current Atherosclerosis Reports, 2016, 18, 8.	4.8	3
836	Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus. Lupus, 2016, 25, 741-748.	1.6	4
837	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circulation Research, 2016, 118, 579-585.	4.5	131
838	Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes and Endocrinology, the, 2016, 4, 436-446.	11.4	28
839	Dyslipidemia Part 2. Vascular and Endovascular Surgery, 2016, 50, 119-135.	0.7	4
840	Evidence-Based Medicine and Comparative Effectiveness Research. , 2016, , 339-356.		0
842	Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis, 2016, 246, 121-129.	0.8	3
843	Almanac 2015: coronary artery disease. Heart, 2016, 102, 492-499.	2.9	7
844	Dyslipidemia in Obesity. , 2016, , 525-540.		4
845	Time-related trends in variability of cIMT changes in statin trials. Data in Brief, 2016, 6, 530-541.	1.0	1
846	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opinion on Pharmacotherapy, 2016, 17, 369-380.	1.8	43
847	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5
848	Lipodystrophy Syndromes. , 2016, , 648-661.e5.		4
849	Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic Advances in Chronic Disease, 2017, 8, 4-11.	2.5	44

#	ARTICLE	IF	CITATIONS
850	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	1.9	5
851	Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. <i>Clinical Therapeutics</i> , 2017, 39, 620-629.	2.5	5
852	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	2.1	766
853	Human genetic insights into lipoproteins and risk of cardiometabolic disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 113-119.	2.7	12
854	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , 2017, 35, 40-46.	2.5	12
855	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. <i>Journal of Clinical Lipidology</i> , 2017, 11, 929-937.	1.5	9
856	Dyslipidemia in diabetes mellitus and cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 27-32.	0.8	41
857	Evaluation of Antiatherogenic Properties of Ezetimibe Using ³ H-Labeled Low-Density-Lipoprotein Cholesterol and ^{99m} Tc-cAbVCAM1 ⁵ SPECT in ApoE ^{-/-} Mice Fed the Paigen Diet. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1088-1093.	5.0	19
858	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. <i>The Cochrane Library</i> , 2017, , .	2.8	2
859	A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. <i>International Journal of Cardiology</i> , 2017, 235, 49-55.	1.7	24
860	Carotid artery plaques and intima medial thickness in familial hypercholesterolemia patients on long-term statin therapy: A case control study. <i>Atherosclerosis</i> , 2017, 256, 62-66.	0.8	23
861	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	2.4	45
862	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 169-181.	2.2	19
863	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	61
864	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. <i>BMJ Open</i> , 2017, 7, e014150.	1.9	34
865	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1200.	2.8	1
866	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
867	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia patients withdrawing from regular apheresis. <i>Atherosclerosis</i> , 2017, 265, 225-230.	0.8	20

#	ARTICLE	IF	CITATIONS
868	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1099-1104.	3.3	16
869	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 1161-1167.e3.	1.5	42
870	Familial hypercholesterolaemia. Nature Reviews Disease Primers, 2017, 3, 17093.	30.5	315
871	Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1769555.	0.4	0
872	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology, 2017, 24, 1383-1401.	1.8	43
873	Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. International Journal of Epidemiology, 2017, 46, 1777-1785.	1.9	10
874	Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nature Reviews Cardiology, 2017, 14, 21-29.	13.7	131
875	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German <sc>DIVE</sc> and <sc>DPV</sc> registries. Diabetes, Obesity and Metabolism, 2017, 19, 61-69.	4.4	9
876	Leveraging human genetics to guide drug target discovery. Trends in Cardiovascular Medicine, 2017, 27, 352-359.	4.9	26
877	Potential effect of ezetimibe against <i>Mycobacterium tuberculosis</i> infection in type II diabetes. Respiriology, 2017, 22, 559-566.	2.3	10
878	Factors Correlated with Slower Rates of Arteriosclerosis in the Carotid Arteries. Health Evaluation and Promotion, 2017, 44, 479-484.	0.0	0
879	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.9	70
880	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 343-351.	2.3	14
881	Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget, 2017, 8, 41582-41589.	1.8	16
882	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
884	Familial hypercholesterolemia: experience from the French-Canadian population. Current Opinion in Lipidology, 2018, 29, 59-64.	2.7	25
885	Evolving Role of Non-Statins for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy, 2018, 38, 164-171.	2.6	7
886	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. International Journal of Cardiology, 2018, 252, 193-198.	1.7	34

#	ARTICLE	IF	CITATIONS
887	Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs, 2018, 18, 157-173.	2.2	130
888	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. Critical Reviews in Food Science and Nutrition, 2018, 58, 958-971.	10.3	27
889	Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. Journal of Evaluation in Clinical Practice, 2018, 24, 222-231.	1.8	7
890	Dynamic interactions of n-3 and n-6 fatty acid nutrients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 136, 15-21.	2.2	39
891	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 2018, 39, 3521-3527.	2.2	44
892	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. Clinical Pharmacology and Therapeutics, 2018, 103, 409-418.	4.7	42
893	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature Reviews Nephrology, 2018, 14, 57-70.	9.6	192
894	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 9-15.	3.3	13
895	Effect and safety of combination lipid-lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events. Aging Medicine (Milton (N S W)), 2018, 1, 176-184.	2.1	1
896	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2018, 2018, CD012502.	2.8	53
897	Familial Hypercholesterolemia. , 2018, , 285-297.		0
898	Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, 277, 483-492.	0.8	128
899	Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Atherosclerosis, 2018, 277, 524-529.	0.8	6
900	Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. Current Cardiology Reports, 2018, 20, 125.	2.9	15
901	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. Journal of the American Heart Association, 2018, 7, e009778.	3.7	67
902	Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied. Frontiers in Cardiovascular Medicine, 2018, 5, 116.	2.4	7
903	Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Medical Hypotheses, 2018, 121, 60-63.	1.5	16
904	PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?. Journal of Clinical Lipidology, 2018, 12, 1106-1108.	1.5	5

#	ARTICLE	IF	CITATIONS
905	Mendelian randomization: Its impact on cardiovascular disease. <i>Journal of Cardiology</i> , 2018, 72, 307-313.	1.9	23
906	Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. <i>Journal of Clinical Lipidology</i> , 2018, 12, 999-1007.	1.5	6
907	Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2018, 82, 757-766.	1.6	31
908	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. <i>Lipids in Health and Disease</i> , 2018, 17, 8.	3.0	8
909	Applying the ordinal model of atherosclerosis to imaging science: a brief review. <i>Open Heart</i> , 2018, 5, e000861.	2.3	6
910	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	21
911	Disorders of Lipid Metabolism. , 2018, , 755-780.		3
912	Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 751-770.	2.0	171
913	Cholesterol screening and statin use in children: a literature review. <i>Irish Journal of Medical Science</i> , 2019, 188, 179-188.	1.5	7
914	More- Versus Less-Intensive Lipid-Lowering Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005460.	2.2	8
915	Effects of ezetimibe/simvastatin 10/10â€‰mg versus Rosuvastatin 10â€‰mg on carotid atherosclerotic plaque inflammation. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 201.	1.7	8
916	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 414-422.	3.1	34
917	An update on pharmacotherapies in diabetic dyslipidemia. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 334-341.	3.1	24
918	Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. <i>Atherosclerosis</i> , 2019, 282, 143-147.	0.8	12
919	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 547.	3.5	14
920	Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice. <i>Molecular Pharmacology</i> , 2019, 96, 47-55.	2.3	16
921	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. <i>Science China Life Sciences</i> , 2019, 62, 758-770.	4.9	15
922	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. <i>Medicine (United States)</i> , 2019, 98, e14400.	1.0	29

#	ARTICLE	IF	CITATIONS
923	Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Chemical and Pharmaceutical Bulletin, 2019, 67, 419-425.	1.3	4
924	Emerging Lipid-Lowering Therapies in Secondary Prevention. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
925	Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System. Pharmaceuticals, 2019, 12, 40.	3.8	18
926	The emerging concept of "individualized cholesterol-lowering therapy" A change in paradigm. , 2019, 199, 111-116.		34
927	Statins: Rationale, Mode of Action, and Side Effects. , 2019, , 171-200.		6
928	Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. Blood Purification, 2019, 47, 301-316.	1.8	6
929	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2019, 20, 917-928.	1.8	17
930	Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study. Scientific Reports, 2019, 9, 4545.	3.3	30
931	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42 Neurology, 2019, 21, 22.	1.8	16
932	Guidelines impact cholesterol management. Journal of Clinical Lipidology, 2019, 13, 432-442.	1.5	6
933	Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders. , 2019, , 487-515.		0
934	A Control-Theoretic Model of Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 785.	4.1	12
935	A sustainable catalytic enantioselective synthesis of norstatine derivatives. Organic and Biomolecular Chemistry, 2019, 17, 9792-9798.	2.8	4
936	Management of Lipid Abnormalities in Patients with Diabetes. Current Cardiology Reports, 2019, 21, 147.	2.9	15
937	Coronary Atherosclerosis in Masters Athletes: Mechanisms and Implications for Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 87.	0.9	4
938	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2019, 132, 16-24.	1.5	5
939	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy, 2019, 8, 5-20.	2.6	17
940	Development and Validation of RP-LC Method for the Simultaneous Determination of Simvastatin and Ezetimibe in Fixed-Dose Combination Tablets and in Rabbit Serum. Chromatographia, 2019, 82, 279-285.	1.3	5

#	ARTICLE	IF	CITATIONS
941	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	2.8	1,550
942	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1046-e1081.	1.6	361
943	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
944	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 3168-3209.	2.8	1,128
945	Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041.	2.2	23
946	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	12.2	6
947	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. Heart, 2019, 105, 567-578.	2.9	13
948	Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. Progress in Lipid Research, 2019, 73, 65-91.	11.6	155
949	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. Trends in Cardiovascular Medicine, 2020, 30, 151-157.	4.9	3
950	The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. Clinical Genetics, 2020, 97, 457-466.	2.0	22
951	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.8	21
952	Statins in primary prevention: is the enthusiasm justified?. Indian Heart Journal, 2020, 72, 221-224.	0.5	0
953	Controlling the thickness of the atherosclerotic plaque by statin medication. PLoS ONE, 2020, 15, e0239953.	2.5	7
954	The effect of simvastatin on gene expression of low-density lipoprotein receptor, sterol regulatory element-binding proteins, stearyl-CoA desaturase 1 mRNA in rat hepatic tissues. Archives of Physiology and Biochemistry, 2022, 128, 1383-1390.	2.1	2
955	The Impact of Information Technology on the Diffusion of New Pharmaceuticals. American Economic Journal: Applied Economics, 2020, 12, 1-39.	2.9	5
956	Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor. Frontiers in Genetics, 2020, 11, 554931.	2.3	5
957	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy, 2020, 21, 2137-2151.	1.8	7
958	Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases. Frontiers in Medicine, 2020, 7, 467.	2.6	61

#	ARTICLE	IF	CITATIONS
959	The Effect of Long-Term Aronia melanocarpa Extract Supplementation on Cognitive Performance, Mood, and Vascular Function: A Randomized Controlled Trial in Healthy, Middle-Aged Individuals. <i>Nutrients</i> , 2020, 12, 2475.	4.1	21
960	Grape juice attenuates left ventricular hypertrophy in dyslipidemic mice. <i>PLoS ONE</i> , 2020, 15, e0238163.	2.5	6
961	miRNA-146b-5p protects against atherosclerosis by inhibiting vascular smooth muscle cell proliferation and migration. <i>Epigenomics</i> , 2020, 12, 2189-2204.	2.1	11
962	Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. <i>Lipids in Health and Disease</i> , 2020, 19, 111.	3.0	20
963	The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HJ-PROPER Sub-Analysis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 548-555.	2.0	1
964	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
965	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
966	Drugs for the Skinternist. , 2021, , 430-444.e3.		0
967	Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 134-142.	1.5	6
968	Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. <i>Cardiology Research</i> , 2021, 12, 98-108.	1.1	8
969	Ezetimibe. <i>Stroke Revisited</i> , 2021, , 91-101.	0.2	1
970	Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants. <i>Journal of Clinical Lipidology</i> , 2021, 15, 142-150.e2.	1.5	5
972	The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1133-1145.	1.9	8
973	Influence of lipid-lowering drugs on inflammation: what is yet to be done?. <i>Archives of Medical Science</i> , 2021, , .	0.9	6
974	Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?. <i>Thrombosis Research</i> , 2021, 200, 156-163.	1.7	1
975	Lipid Optimization in Lower Extremity Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2021, 76, 542-554.	0.9	3
976	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110236.	2.0	4
977	Trends in lipid-modifying agent use in 83 countries. <i>Atherosclerosis</i> , 2021, 328, 44-51.	0.8	57

#	ARTICLE	IF	CITATIONS
978	Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. American Journal of Cardiology, 2021, 154, 22-28.	1.6	4
979	Atualiza��o da Diretriz Brasileira de Hipercolesterolemia Familiar �� 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 782-844.	0.8	10
980	Lipoprotein metabolism in familial hypercholesterolemia. Journal of Lipid Research, 2021, 62, 100062.	4.2	31
982	Diabetes Mellitus and Cardiovascular Disease. , 2011, , 227-252.		2
983	The Metrics and New Imaging Marker Qualification in Medical Imaging Modalities. , 2014, , 27-45.		1
984	Lipidsenkende Mittel. , 2010, , 665-680.		1
985	Lipidsenkende Mittel. , 2011, , 683-698.		1
986	Lipidsenkende Mittel. , 2015, , 745-756.		1
987	Transparency and Conflicts in Science: History of Influence, Scandal, and Denial. Accounting, Finance, Sustainability, Governance & Fraud, 2020, , 3-26.	0.4	3
988	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. , 2010, , 81-86.e2.		3
989	PCSK9 inhibitors in the current management of atherosclerosis. Archivos De Cardiologia De Mexico, 2017, 87, 43-48.	0.2	8
990	20 Brain Imaging in the Evaluation of Putative Alzheimer��s Disease-Slowing, Risk-Reducing and Prevention Therapies. , 2009, , 319-350.		10
991	Venous and arterial disease in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1095-1113.	2.8	61
992	Shifting views on lipid lowering therapy. BMJ: British Medical Journal, 2010, 341, c3531-c3531.	2.3	23
993	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. Journal of Lipid and Atherosclerosis, 2019, 8, 183.	3.5	16
994	Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship. PLoS ONE, 2009, 4, e5092.	2.5	7
995	The Relationships of Markers of Cholesterol Homeostasis with Carotid Intima-Media Thickness. PLoS ONE, 2010, 5, e13467.	2.5	39
996	ULTRASOUND MARKERS OF PREMANIFEST ATHEROSCLEROSIS OF CAROTID AND FEMORAL ARTERIES IN ASSESSMENT OF CARDIOVASCULAR RISK. Russian Journal of Cardiology, 2018, , 92-98.	1.4	7

#	ARTICLE	IF	CITATIONS
998	Conflict of Interest in Medical Research, Education, and Practice. , 2009, , .		163
999	Surrogate outcome markers in research and clinical practice. Australian Prescriber, 2009, 32, 47-50.	1.0	19
1000	Promoting Transparency in Pharmaceutical Industryâ€“Sponsored Research. American Journal of Public Health, 2012, 102, 72-80.	2.7	65
1001	Ezetimibe Therapy for Dyslipidemia: An Update. Current Pharmaceutical Design, 2013, 19, 3107-3114.	1.9	40
1002	Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials. Current Pharmaceutical Design, 2020, 26, 11-24.	1.9	7
1003	Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis. Current Vascular Pharmacology, 2011, 9, 220-237.	1.7	13
1004	Lipid management in Type 2 diabetes: the case for combination therapy?. Therapy: Open Access in Clinical Medicine, 2011, 8, 129-141.	0.2	2
1005	Risk factors for venous and arterial thrombosis. Blood Transfusion, 2011, 9, 120-38.	0.4	294
1006	Percutaneousl US approach to diagnosis and treatment of atherosclerosis. Choonpa Igaku, 2010, 37, 469-477.	0.0	2
1007	Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World Journal of Gastroenterology, 2010, 16, 5958-64.	3.3	26
1008	The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients. Korean Journal of Internal Medicine, 2009, 24, 233.	1.7	10
1009	Duodenal Niemann-Pick C1-like 1 expression was negatively correlated with liver X receptor expression in nonalcoholic fatty liver disease. Korean Journal of Internal Medicine, 2019, 34, 777-784.	1.7	6
1010	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes and Metabolism Journal, 2020, 44, 213.	4.7	43
1011	Letter to the Editor Atorvastatin in combination with ezetimibe and carotid atherosclerosis. Genetics and Molecular Research, 2014, 13, 4805-4807.	0.2	5
1012	Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss Medical Weekly, 2012, 142, w13705.	1.6	87
1013	Intima-Media Thickness of Lower-Limb Arteries Associated with Fasting and Post-Challenge Plasma Glucose Levels. Journal of Atherosclerosis and Thrombosis, 2009, 16, 748-755.	2.0	8
1014	WpÅ, yw krÃ³tkotrwaÅ, ego leczenia skojarzonego simwastatynÃ... i ezetimibem na stÃ™Å¼enie adipokin w osoczu pacjentÃ³w na izolowanÃ... hipercholesterolemiÃ™. Endokrynologia Polska, 2014, 65, 275-280.	1.0	2
1016	Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease. Acta Cardiologica Sinica, 2016, 32, 578-585.	0.2	13

#	ARTICLE	IF	CITATIONS
1017	Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Journal of Inflammation Research, 2021, Volume 14, 5319-5335.	3.5	2
1018	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 713007.	3.5	6
1019	The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis. Trends in Molecular Medicine, 2021, 27, 1095-1105.	6.7	17
1020	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Failure Clinics, 2021, 18, 177-188.	2.1	14
1021	Atherosclerosis and lipoprotein metabolism. , 2007, , 321-330.		6
1022	Lipidsenkende Mittel. , 2008, , 645-659.		0
1023	Regression of Atherosclerosis: Where are We Now, and Where are We Going?. Methodist DeBakey Cardiovascular Journal, 2021, 4, 18.	1.0	0
1024	ŕ¼ŕ¼ŽJIKEI HEARTç”ç©ŕ. Japanese Journal of Clinical Pharmacology and Therapeutics, 2008, 39, 157-161.	0.1	0
1025	Cardiovascular Disease Risk Management in Diabetes â€” The Implications of the REALITY Asia Study. Asia Pacific Cardiology, 2008, 2, 12.	0.0	0
1026	The ENHANCE Study: What Do We Know Now?. MD Conference Express, 2008, 8, 6-30.	0.0	0
1027	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 528-532.	1.0	0
1028	Lipid Screening in Children and Adolescents. Pediatric Annals, 2008, 37, 757-62.	0.8	0
1029	Lipidsenkende Mittel. , 2009, , 637-652.		0
1030	Coronary Artery Disease Prevention. , 2009, , 17-32.		0
1031	Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound. , 2009, , 420-431.		1
1032	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, 40, 137S-138S.	0.1	0
1033	Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition, 2009, 18, 33-50.	0.1	0
1034	Maintaining Cardiovascular Health in Patients With Mixed Dyslipidemia Optimizing the Management of Hypertriglyceridemia and Non-HDL Cholesterol. Journal of Managed Care Pharmacy, 2009, 15, 1-22.	2.2	0

#	ARTICLE	IF	CITATIONS
1035	Achieving lipid targets with combination therapy. Independent Nurse, 2009, 2009, .	0.1	0
1036	What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention?. Cor Et Vasa, 2009, 51, 131-135.	0.1	0
1037	Treatments for severe psoriasis: update. Australian Prescriber, 2009, 32, 50.	1.0	0
1038	Nuevas alternativas farmacológicas en dislipidemias. Medwave, 2009, 9, .	0.5	0
1039	Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. Fundamental and Clinical Cardiology, 2009, , 19-36.	0.0	0
1040	The ESCAPE randomized clinical trial: 20-80 mg of Zokor (Simvastatin) in patients with familial hypercholesterolemia in ischemia heart disease. Part 1. Hypolipidemic efficacy, safety and tolerance. Arterial Hypertension (Russian Federation), 2009, 15, 543-549.	0.4	0
1041	Dyslipidemia: Pathogenesis and Management. , 2010, , 435-456.		0
1042	Geeft de combinatie van een statine met ezetimibe een (verhoogde) kans op regressie van coronairsclerose?. , 2010, , 78-83.		0
1043	Recent Cholesterol-Lowering Drug Trials: New Data, New Questions. , 2010, , 185-191.		0
1044	Biomarkers. , 2010, , 225-239.		0
1045	Ezetimibe in the Treatment of Patients with Metabolic Diseases. European Endocrinology, 2010, 9, 55.	1.5	0
1046	ĩ¼ĩ¼Žâ«è„îĩ-âĒ-æ€Œ-¾æ,îã®âfâ,â,âfžâf¼ã,«âf¼. Japanese Journal of Clinical Pharmacology and Therapeutics, 2010, 41, 909-914.		0
1047	Hyperlipidemia effects on clinical indexes of stroke in Japanese patients. Nosotchu, 2010, 32, 242-253.	0.1	2
1048	Lipodystrophy Syndromes. , 2010, , 722-734.		2
1049	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2010, , 788-807.		0
1051	New combination drugs in lipid management. Cardiovascular Medicine(Switzerland), 2010, 13, 191-196.	0.0	0
1052	Evidence-based data on Simvastatin: A 15-year experience. Arterial Hypertension (Russian Federation), 2010, 16, 238-249.	0.4	0
1053	Management of Dyslipidemia. , 2011, , 59-89.		0

#	ARTICLE	IF	CITATIONS
1054	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
1055	Genetic Disorders of the Lipoprotein Metabolism; Diagnosis and Management. , 2011, , 305-330.		0
1056	Drug Therapy and Follow-Up. , 2011, , 563-631.		0
1058	Die Entwicklung der Arzneimittelausgaben im deutschen Gesundheitssystem. , 2011, , 139-158.		0
1060	Lipid management after a coronary event. , 2011, , 328-337.		0
1062	Modern ultrasound methods and atherosclerosis assessment in patients with familial hypercholesterolemia. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 113-122.	1.4	3
1063	Ineffective statin monotherapy: alternative therapeutic strategy. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 110-116.	1.4	0
1064	Hyperlipidemia. , 2012, , 141-151.		1
1065	A closer look at lipid management following an acute coronary syndrome. , 2011, , 45-54.		0
1066	Biomarkers and Coronary Atherosclerotic Burden and Activity as Assessed by Coronary Angiography and Intra-Coronary Imaging Modalities. , 0, , .		0
1068	Lipidsenkende Mittel. , 2012, , 697-711.		0
1070	Conflitto di interessi: Considerazioni e raccomandazioni. , 2012, , 327-336.		0
1071	Drugs that affect lipid metabolism. Side Effects of Drugs Annual, 2012, , 723-730.	0.6	0
1072	Fibers and Prevention of Cardiovascular Disease. , 2012, , 199-232.		0
1073	Inflammation of adipose tissue (Part 6). The effects of medicamental preparations. Problemy Endokrinologii, 2012, 58, 67-73.	0.8	2
1075	Novel therapeutic approaches to prevention and regression of atherosclerosis. , 2012, , 428-440.		0
1077	Attention to Prevention. , 2013, , 13-26.		0
1079	Role of Lipoproteins in Carotid Arterial Disease. , 2013, , 29-36.		0

#	ARTICLE	IF	CITATIONS
1080	Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality. Journal of Clinical Medicine Research, 2013, 5, 275-80.	1.2	12
1081	Lipidsenkende Mittel. , 2013, , 687-702.		0
1083	Mipomersen: Pharmacology, Clinical Trials and Its Potential Role in Therapy. Advances in Diabetes and Metabolism, 2013, 1, 16-20.	0.1	0
1084	Dyslipidemia. , 2014, , 489-502.		1
1085	Auswirkungen von Ã–konomisierungsprozessen auf die VersorgungsqualitÄt von Arzneimitteln. , 2014, , 115-139.		0
1086	Lipidsenkende Mittel. , 2014, , 733-746.		0
1088	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. , 2014, , 129-152.		0
1089	Hyperlipidaemia and monoclonal antibodies â€“ paying for outcome. British Journal of Cardiology, 2014, , .	0.2	0
1090	Efficacy and safety of Mertenil (rosuvastatin) 40 mg in patients with familial hypercholesterolemia. Systemic Hypertension, 2014, 11, 42-47.	0.6	1
1091	Drug trial supports importance of low cholesterol to treat heart disease. Nature, 0, , .	27.8	0
1092	Evidence-Based Medicine and Comparative Effectiveness Research. , 2015, , 1-19.		0
1094	Familial Hypercholesterolemiaâ€™. , 2015, , .		0
1095	Update on the Pharmacologic Agents for Dyslipidemia. Journal of Korean Diabetes, 2015, 16, 269.	0.3	0
1097	Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. Arquivos Brasileiros De Cardiologia, 2016, 106, 247-9.	0.8	1
1098	OBSOLETE: Familial Hypercholesterolemia. , 2018, , .		0
1099	Extracranial Carotid Duplex Ultrasonography. Part II - Clinical Utility of Carotid Duplex Ultrasound. Journal of Neurosonology and Neuroimaging, 2018, 10, 61-79.	0.1	3
1100	Hemodynamic impact of positive end expiratory pressure in right cardiac performance. Journal of Cardiology & Current Research, 2019, 12, 131-133.	0.1	1
1101	FAMILIAL HYPERCHOLESTEROLEMIA: DIAGNOSTIC ISSUES AND THERAPEUTIC POSSIBILITIES. Kuban Scientific Medical Bulletin, 2019, 26, 175-186.	0.4	0

#	ARTICLE	IF	CITATIONS
1102	Ezetimibe in the treatment of hypercholesterolaemia. Interni Medicina Pro Praxi, 2019, 21, 112-116.	0.0	0
1104	Familial hypercholesterolemia: clinical pearls. Journal of Cardiology & Current Research, 2019, 12, 127-129.	0.1	0
1105	Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Annals of Gastroenterology, 2020, 33, 603-614.	0.6	13
1107	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 0, , .	0.5	0
1108	Carotid Artery Temperature Reduction with Statin Therapy in Patients with Familial Hyperlipidemia Syndromes. Journal of Clinical Medicine, 2021, 10, 5008.	2.4	1
1109	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. Contemporary Cardiology, 2021, , 219-268.	0.1	0
1110	Genetic Disorders of Lipoprotein Metabolism. Contemporary Cardiology, 2021, , 35-80.	0.1	0
1111	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. Contemporary Cardiology, 2021, , 107-120.	0.1	0
1112	Probiotics as an Alternative Food Therapy. Advances in Environmental Engineering and Green Technologies Book Series, 2020, , 97-127.	0.4	0
1113	A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. Mayo Clinic Proceedings, 2009, 84, 221-8.	3.0	17
1114	Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clinic Proceedings, 2009, 84, 811-21.	3.0	21
1116	Dyslipidemia and its Treatment in HIV Infection. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 112-8.	2.9	38
1117	Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?. MAJ, 2012, 7, 153-62.	0.1	13
1118	Exercise training in aging and diseases. Translational Medicine @ UniSa, 2012, 3, 74-80.	0.5	7
1120	An overview of cholesterol management. American Health and Drug Benefits, 2008, 1, 39-48.	0.5	14
1121	Does ezetimibe modify clinical outcomes?. Canadian Family Physician, 2015, 61, 251.	0.4	1
1122	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Canadian Family Physician, 2016, 62, 32-7.	0.4	36
1123	A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease. European Review for Medical and Pharmacological Sciences, 2015, 19, 2628-2633.	0.7	4

#	ARTICLE	IF	CITATIONS
1124	Common sense treatment for common lipid disorders. Missouri Medicine, 2011, 108, 107-12.	0.3	0
1126	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 2019, 48, 1405-1417.	0.5	0
1127	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 70-104.	0.5	13
1128	Cholesterol-Lowering Drugs. , 2020, , 233-248.		0
1129	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
1130	Probiotics as an Alternative Food Therapy. , 2022, , 543-565.		0
1131	Barriers to prescribing proprotein convertase subtilisin/kexin type 9 inhibitors after coronary revascularisation. Internal Medicine Journal, 2022, , .	0.8	2
1134	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in Therapy, 2022, 39, 1857-1870.	2.9	7
1135	The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia. Current Atherosclerosis Reports, 2022, 24, 379-389.	4.8	5
1136	Repurposing of Various Current Medicines as Radioprotective Agents.. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, .	1.7	0
1137	Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2022, 24, 407-418.	4.8	9
1138	Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms. Trends in Cardiovascular Medicine, 2023, 33, 170-179.	4.9	2
1139	Treatment goals in familial hypercholesterolaemia—time to consider low-density lipoprotein-cholesterol burden. European Journal of Preventive Cardiology, 2022, 29, 2278-2280.	1.8	5
1140	Medical Optimization of the PAD Patient. Seminars in Vascular Surgery, 2022, 35, 113-113.	2.8	0
1144	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3
1145	Drugs for the skinternist. , 2013, , 408-423.e3.		0
1146	Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. Journal of Clinical Lipidology, 2022, 16, 562-573.	1.5	4
1147	The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. , 2022, 1, 2-13.		0

#	ARTICLE	IF	CITATIONS
1148	The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. <i>Inflammopharmacology</i> , 2022, 30, 1597-1615.	3.9	5
1149	Bempedoic Acid, an Atp Citrate Lyase Inhibitor, Reduces Intimal Hyperplasia Via Activation of Ampk± Signaling Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1150	Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE±/± Mice Fed High-Fat Diet. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3145-3168.	4.3	1
1151	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	12
1152	Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPK± signaling pathway. <i>International Immunopharmacology</i> , 2022, 113, 109392.	3.8	3
1153	The Program on the Surgical Control of the Hyperlipidemias (POSCH) and the Lipid Regulatory Hypothesis. <i>EMJ Cardiology</i> , 0, , 67-76.	0.0	3
1155	Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16224.	4.1	6
1156	Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 531-557.	2.0	15
1157	Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 558-586.	2.0	16
1158	Approach To Diagnosis And Treatment Of Familial Hyperlipidemia. , 0, , .		0
1159	Ronda clÁnica y epidemiol³gica. <i>Iatreia</i> , 2008, 21, .	0.1	0
1160	Glycated Hemoglobin is a Significant Predictor of Femoral, but Not of Carotid or Popliteal, Intima-Media Thickness in Adolescents with Type 1 Diabetes: A Case-Series Study. <i>Pediatric Diabetes</i> , 2023, 2023, 1-10.	2.9	0
1161	A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. <i>Reviews in the Neurosciences</i> , 2023, .	2.9	0
1162	The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	0
1163	A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD. <i>Cells</i> , 2023, 12, 1648.	4.1	4
1164	Recent advances in the management and implementation of care for familial hypercholesterolaemia. <i>Pharmacological Research</i> , 2023, 194, 106857.	7.1	4
1165	Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 477-495.	2.2	9
1166	Trends and hotspots in familial hypercholesterolemia: A bibliometric systematic review from 2002 to 2022. <i>Medicine (United States)</i> , 2023, 102, e34247.	1.0	0

#	ARTICLE	IF	CITATIONS
1167	High Cholesterol Disorders, Myocardial Infarction and Its Therapeutics. World Journal of Cardiovascular Diseases, 2023, 13, 433-469.	0.2	1
1168	Virtual Screening of Potential RoxS Inhibitors and Evaluation of Their Antimicrobial Activity in Combination with Antibiotics against Clinically Resistant Bacteria. Antibiotics, 2023, 12, 1422.	3.7	0
1169	Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PLACS Data. Journal of the American Heart Association, 2023, 12, .	3.7	9
1170	Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition. British Journal of General Practice, 2024, 74, e174-e182.	1.4	0
1171	Interplay of Cholesterol and Actin in Neurotransmitter GPCR Signaling: Insights from Chronic Cholesterol Depletion Using Statin. ACS Chemical Neuroscience, 2023, 14, 3855-3868.	3.5	0
1172	Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia. Korean Journal of Internal Medicine, 2023, 38, 797-809.	1.7	1
1173	Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Lithuania), 2023, 59, 1980.	2.0	0
1174	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. Journal of Atherosclerosis and Thrombosis, 2023, , .	2.0	2
1176	Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia. European Journal of Preventive Cardiology, 0, , .	1.8	1
1178	Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals, 2024, 17, 289.	3.8	0
1179	Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases, 2024, 33, 107647.	1.6	0
1180	Advances in familial hypercholesterolemia. Advances in Clinical Chemistry, 2024, , 167-201.	3.7	0